var title_f26_44_27328="Transabdominal cerclage";
var content_f26_44_27328=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F65514&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F65514&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transabdominal cerclage",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 439px; height: 311px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAE3AbcDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiionuIY5kheWNZXUsqFgGYDGSB6DI/MUAS0U3zY/76/nR5sf99fzoHZjqKb5sf8AfX86PNj/AL6/nQFmOopvmx/31/OjzY/76/nQFmOoqGa6t4QpmnijDMqKWcDLMcAD3JIAFTUCCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoqEXVuZ5IBPEZ4wrPHvG5Qc4JHUA4OPoak82P++v50DsOopvmx/wB9fzo82P8Avr+dAWY6im+bH/fX86PNj/vr+dAWY6im+bH/AH1/Oo2urdZ4oWniE0uTHGXG58dcDvigViaiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuW8Yj7PrHhy/yQq3T2j/7ssZx/wCPpHXU1zvxCjdvCF/PEMy2YS9T6wuJP/ZMfjQOLsy5RTY3WWNZIyGRwGUjuDTqg6QooooAKKKKAMTxdxptrJ/zz1Czf8riOuxrkfF+B4a1CU/8sI/tH/fsh/8A2WtLxl4gh8N+EdT1uTDJa25kRezueEX/AIExUfjVIxqbm5RXgvgb4k69a+E/E41WYa1rGjJDf5liMBktnVTKANo/1Z3845roLr4n31xpEd7pEFh/p2pT2ulrKsjm7giU5lGCoHzA9SAAO/SmZnrVFeI3nxi1UaFoWpxaZZW1pd2X2q5uJfMmSJ/NaPaVj+dFOwneQRzgAkGtsfEXVLi18Q6paxaMmm6Y99ClpNOwu5Xt4ncHHT5in3cZC5OeKAPU6K8O8d/Ey7vPD9xBo08UEh0fT9UN1Zz5eKSW8jjeLI6DafrzW5f/ABMvbf4gQaTb29ldaS+qppMkqB1kilZMnJJwSD1AXGP4s0Aeq0Vxvwx8S6v4s0RdX1CysLWymMiQCCZ3kYpK6MWBUBR8oxgnv06V2VABRRRQBDeGIWk5uX2QeW3mNuK4XHJyORx3r558E+J5rPQLo+HdZ87ULzxXFpnmXU8l4IrSR2WJgjv0+8QQQWxyeBj6MooA+frvxT4lOqaUNT8SrZw6d4ku9JuLxLfy4plWFWQyoG2nJYgKeM4PUVdPxE8TjxnqNrPcWFrHb3VzANNnVVk8pFby5U/jYkgMT9wgnpXulFAHjdl4l8YXek+B3bWrCOfxK/Lpp3FuvkF8YL/McjrwPbtXNat8UvEcHhewf+04rfVUhvnkla2jSG6MEpQAFs/OQv3FHfOQK+iaKAPL/hbqM+q+O/Ft5cEB7jT9HnKKTtVngdjgdhk1mjx1r48dvYefCXGsSWJ0b7Kd6WSxlheb/vYOAfQ5wOa9iooA8j+DvjbWfEviC/s9ZvEuzFbecTZxRtaoS+AFkU7lOM/JIN2MnjHPrlFB4FAHJ2EW7xP4iuc5DSwwD2CRKcfm5rWrB8HSG5025viSVvbyedM/3PMKp/46q1vVDOmKsgooooGFFFFABWToafb/ABjqV4eYtPhWyiPbzHxJL+nkj860riVIIJJpTtjjUux9ABk1B4BtpIfDFtPcLtub4tfTDuGlYvg/QEL/AMBpozqPQ6GiiiqMQooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACorqBLm2mglXdHKhRh6gjBqWigDjfBEkj+FrCOf8A11sptJPXdExjP6rW5WRpDJDrGv2KjaYrsTAeqyor5/763/lWvUM6Yu6CiiigYUUUUAQ3lvHd2k9tON0UyNG49QRg/wA6p+E47fWvB1ja6xbW929ofs08c8YkXzoW27sHvlQw+oNaVYS3C+HPEUlzOwTSNUKLK56QXIwqsfRXXapJ6Mq/3qaM6iujpptK06e9e8msLSS7eA2rzvCpdoScmMsRkpnnb0rKvLLwlstdDvbbQtlv+8t9PmjhxH1+ZIz06nkD1roq8c8RfDrWpPF+q65YvYw2c7STyxqzTyXGIioURNGdjk4+ZZPotUYndR6X4KmEZjsfDkg0yMMhWGA/ZEJLAjj5Bklu3XNWI4fCd1LN4gij0KaRVMcupKsTEAjBVpfTBxgnoa8n8I/DrxHc+GYLsJpei3p8PDTYIjCzPI7Mrs1yrIAD8uMYbBOe2KtWPwn1uO21JpJdKDy6lZajFaNPLPDMYUZXjmYoDhi2chTyBxjigD0NdO8C21jHItn4Zis7wCFGEUCxzgPvCg4w2HAbHqM9a15fDehy6p/aUujaa+o71k+1NaxmXevCtvxnI7HPFeW+JvhfrGt3lvftbaBEWtJbO402CaSGBA0rOHRxGSWOfm+RckAgivW9GtWsdIsbSQgvBBHExDFgSqgHk8np1PNAEmn2Npp1olrp9rBa2yElYYIwiKSSTgDgZJJPuTViiigAooooAKKKKACiimQzRTpvgkSRMldyMCMgkEZHcEEfhQA+iiigAooooAK5/wAZ6pJYaUbawBfVb7MFmijOHI5c+iqDuJPpjqQK6CuOsJDqninVdSyTb2v/ABLrb0O05mb8Xwv/AGzpMqKuzR0uyi03TbSyt8+VbRLEmeuFGB/KrVFFSdAUUUUAFFFFAGJ4wd/7Ea1hbbNfSx2Sf9tHCsfwUsfwrsFUKoVQAoGAB2rkrpftfjHQrXgpbrPfOPdVES/rKT+FddVIwqPUKKKKZAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRTY3WRA8bKyHoynINAHLaiv2Tx3C+QE1GwKH/fhfI/NZm/75rVrP8AHS+RBpWpDA+w30Zdj2jkzE34fvAf+A1oVLN6b0CiiikWFFFFABUV1bw3dtLb3MSSwSqUeNxlWU8EEelS0UAY3h+9k0K+g0LUppJbWbI067lOScc+Q7d3AGVJ+8oPdST19c9qen22p2UlpeR74XweCQVIOQwI5DAgEEcgisRvFl5o1v8A2PfQPeeIWPladgYXUAejkgYUqOZPQAsOCBVJmM421Rv6lrco8Q2ejaXEk90wE947k7La3zjJx/GxBCj2Ynhed2sbwtog0Wxk8+b7VqV05nvbsrgzynqcdlAwqr2UAVs0zMKKKKACiiigAooooAKKKKAMHxnqVzY6SINMKjVr+QWdluGQsjA/OR3CKGc+yGtDQtLt9E0ez02zDeRbRiNSxyzY6sT3JOST3JNc/oX/ABP/ABbf623zWOn79NsPRnBH2iUf8CURg/8ATNv71ddQAUUUUAFFFRXVxDaW0txdSpFBEpd5HbaqgdST2oAy/FmpyaXo7taFDqFw4trRX6NM/C59hyx9lNVdF06LSdKtbGEsyQIFLt1durMfckkn3NZulrNrmqf29fI0cCgpptu4wY4z1lYf339Oy4HUtW/Utm8I2QUUUUiwooooAKKKKAMnSMS+PtQcci306FD7F5JDj8lH6V1lc14HjSa0vtWU7jqVy0qsRj90v7uPHsVTcP8AerXTVLWTWJdMjkLXkUQmkUKSEUnAyegJ9OuKq9tzBpzbcVsXqKKKZAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXI6NZw6N43udP0wNFYXFl9re3z8kcnmbcoP4cjOQPSuurkfEktxoGvDxD5BuNNa2W2vAn+sgUOWEgH8S/Mcjrxms6mlpdjrwl5OVJfaW3d9Pn2N/XrBdV0S/sHxi5geIZ7EjAP4GsjQNQGqaNZ3oBVpYwXU9VccMp9wwI/CukjdZY0kjYMjgMrDoQe9chpi/wBmeJdX0o8RSsNRtgf7shIkUfSQE/8AbQVbMKbs7G3RRRUmwUUUUAFFFFAFXVL+20vTri+v5VhtbdDJI57AfzPt3NctYeH5Ne83WtfjlttRmA+woCPM02MEFdvUCUkBmPPZeQOX2v8AxV+spet83h7Tpc2q9VvLhf8Alr7xochfVgW7KT2FArXKega1cG5TSddVI9UCFo5UGIrxR1ZPRhwWQ8jPGRzXRVzmrabbarafZ7tWIDB0dGKvE46OjDlWHqKr2et3WjSfZvEb+ZaEgQ6oFCr7LOBwjf7fCH/ZOAaTMZQtsdXRXKan8RPCWmllutfsdy9VifzSPwTNc1efHDwfb58qW+uf+uVuR/6ERXRHDVp/DF/cZOSXU9Qorxa5/aC0VSfs2j6jJ/vsifyJrMuP2hl/5d/Dh+r3n+CVqsvxD+z+QvaR7nvlFfOsv7QmoH/VaDaL/vTs39BVZ/2gddP+r0jTR9TIf/ZqtZZiO34i9rE+k65/xpqU9npsVnprhdW1OQWdmcZ2MwJaQj0RAzn/AHcdxXhB+PPihvuaXpf/AH6kP/s9ZMXxo8QTeIl1q507T5Ggga1t0KSBEBYGRh833mKqM+i+5yPLa6aVl94e1ifUOjabbaPpVpp1ihS2to1ijBOTgDqT3J6k9zVyvnqz/aFu1I+26BA47mG4KfoVNdNpfx78OXDBb+y1CzJ/i2rIo/EHP6VEsvxEfsjVSL6nr9Fcvonj/wAK61tFhrdmZG6Ryt5Tn/gL4JpdS8U77mSx8PWx1K+U7HkB220B/wCmknqP7q5b2HWuWcJQdpKxa97Y3NV1Kz0mykvNRuEt7ZOrue/YAdST0AHJ7VyckNz4ou4bnVYZbbR4iJLfT5Rh5nHIkmHoOqx9jy3OALFrozyX0Wo63dHUNQjH7rK7Ibc9zFHzg9txJbtnHFbNZtm0YW1YUUUUjQKKKKACiiigArF8VSyvYR6dZuUvdTk+yRMOqAgl3/4CgZvqB61tVleHwNU8S3+olQbewBsLZvVzgzMPoQiZ9VahEzdkdLa28VnaQ29ugjghQRoo6KoGAPyFcv8ADsCSDW7qTm7m1ScTMf8AZO1QPYKBWj4t1afTbS2hsIVn1G+mFvbRucLuIJLN/sgAk1P4Y0gaJpCWhlM8xdpZ5iMeZIxLM2O3J/Kpes1boaR/d4eTf2mrei3+V7fP0NaiiitTjCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKxvGVpcX3hTVrWyBNxLbOiKOrEjp+PStmilJXTRdObpzU10dzF8Katp+qaVANPlTdBGiSQdHgIGNrL1BGCPwql42VLMafrhyP7Pm2zMP+eEmFfPsDsc/7lV9L8uT4m60zbIpYbKCJY+hmUksZPfBwua6q7t4ry1mtrlBJBMjRyIejKRgj8jUU23HU2xMFTqXj1Sf3q/zM6isLwnNNFbT6ReuXvdLcW7u3WWPGY5P+BLjP+0G9K3aY07hRRRQAVyniGebXdSbw3p0jxwhQ2qXUZwYoiOIVPaR/X+FcnqVq94o1iWwjt7LTESbWb4mO1ib7q4+9K+P4EByfU4HUirXh3R4dE0xLWJ3mlLGWe4k+/PK33pG9yfyGAOAKBbl62gitbaK3to0igiUIkaDCqoGAAPSpaKKBhSMoZSrgMpGCCMgilooA8p8XfCHSLvUF1LSbZoxnM+nwyCJJh/0zJBCN7Y2n/Z61qeF/h18Pb1mij02dr6JQ0trfTSLNGD0JQEAj/aGVPYmvQqztX0i21QRNN5kVzCS0FzA2yWEnurfzByD3BroWLrJcvM7eplKjF6pDbb4e+EbYDyvDumnH9+EP/6Fmr8fhTw7H9zQdKX6Wcf+FZlv4gutEaODxQVe2Pyrq0a7Y854Ey/8sz0+b7h/2eBXWgggEHINS6s3vJ/eZONuhnxaLpUX+q0yyT/dgQf0qylnbIPkt4V+iAVPRU8zfUDm/Gt9NaafBp+lER6tqkv2S1YDmLIJeX/gCBm+oUd62NO0y007TLXT7WBFtbaJYo0IzhVGBXPeHFOueJb/AMQyc2kAbTtNz0KK376Uf77qFHqsYPRq6uR0ijaSRlSNQWZmOAAOpJpAZ114f0a7JN1pOnzk95LZG/mK4nxf4K8ARKqXujxLeTAmG3sAyzSY67UQjI9SRgdyK2ZfEF/ru+PwyqQ2P3f7VnXcr+phT+P2Y4X03CrGkaNaaWZJIRJNdzYM13O2+aY/7THt6AYA7AVca84fDJopUr7nmnh34N6QdQOoatBcpbbsw6a9wJNo/wCmrqBuP+yOB3LV6xa28NpbxwWsMcEEY2pHGoVVHoAOlS0VNStOq7zdzaMFHYKKKKzKCiiigAooooAKKKKAMrxJeXFppjLYKG1C5cW1qp6eY3AJ9lGWPsprb0mwt9D0W3s4S3kWseC7csx6sx9STkn1JNc/oMf9t+JJdWbmw04va2fpJL0ll+gx5Y+j+tdFrWp2uj6ZPe377YIxyAMlieAoHck8AU9ldmTTnJRirnO6Es3ifVrbxDcq0WmW6t/ZsB+8+4YaZ/TI4A7Cuwrm/B8Umi+DITqMZt1hSWYxHloYyzOFPqQpA/Cm2njnQbo6B5V22NdjmlsS0bKHWJdzliR8uBzzippK0bvdmuMknVcY/DHRei/q/qdNRWHpfi3QNU0KPWrTVrX+y5DtFxK/lKDnGCHwQeOhxWmb+zDxobu33SKrIPMXLBjhSOeQTwPWtDlLNFYtl4m0u40qC/uLmKwjmTzAl5KkbKu7bk/MR196v3Gp2FtPbw3N9awzXHEMckqq0v8AugnJ/CgC3RRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcj8Q4UgtLDV4R5d/aXcKxzLwdjyKrIfVSD0NddXK/Ennw5Gvd721Uf9/lrqqzj8b+X6nXUd8PTb7yXy0/zZyfi8NpN/a6/HxbIBbagMf8sSflk/4Ax5/2WY9q1q05okmheKZFeJ1KsjDIYHqCPSuF8OX9vp2r3XhOW6je6sV8y1Uybne2P3Qe+5c7SDzjae9W03qjGnLodPVDXNUttG0ya+vGbyo8AKgy0jE4VFHdmJAA7k1dd1jRnkYKiglmJwAPWuT0ZW8U6tFrtwp/si2J/sqFv+Wp5BumHuMhPRSW/i4k0LvhbSrmOSfWNaCnWb5QHUHctrEMlIEPoM5J/iYk9MY6GiigYUUUUAFFFFABRRRQA10WRGR1DIwwVIyCPQ1gJ9p8JBZbLzbnw+n+us8F5LVf78PcoO8fOB93ptPQ0UXE4p7mjaXMF5axXNpKk1vKoeORDlWU8gg9xXj/AMbviq3g/VovDsED776zDvdwt+9tQ7lNyL0ZgqsQCRzt7V3GhIuj+KJtPg3Cy1GJ7yOL+GKVGUSbfQN5itjpkMe9c/a/DtdW+K+peMfEUayRW7Rw6XavhgAiAGVvfduKjt19Ks52rOx166jpfh7wpZTLFLbWMcMUVtbGJhKcgBIgn3i/QY61jfYL3xERP4mQR2m4NFpSvlAB0M5HEjf7P3B/tdamRRqHjbVJ7o720wR21rGekYeNXeQD+827bn0THc526ls1hHS7EAAAAAAHAApaKKRoFFFFABRRRQAUUUUAFFFFABWP4gvZx5Ol6Ww/ta+ysRxnyIx9+ZvZQePVio71Lr2s2+j20TTMjXNxIILWAuEM8p+6gJ4Ge5PAHNX/AAzo76bDNcXzxz6tdkPdToMLkfdRM8hFHAH1J5JppdTOcraI0dMsbfTNPt7KzQR29ugjRfYevv71zvjBRL4h8JwyANE187lT0LLExU/ga6uuV8X/AC6/4Tk7C/Zfziepq/D935mmD/i/KX/pLOi1G1W90+6tHYqs8TRFh1AYEZ/WvLfCnw51q11LwkuvTaTJpvhm3uoIPs5d3vBOuw+YrKAgC9gWya9arzL4rfEK+8I3v2fSYbK6mhsjfzwTK+8RB9u7cCFUZBH8Rz2rQ5Tmbf4Ra1D4a8P2IbRTcaNPcZVJHRL5JRjzJG8slZABgfK4xnmui8I/DT+zPE2k6hqlrpc9rp+kJZwRFmuGgnW5eVXQuvZWADcHPQAVV1Hx74l1HSvGU+iWem2tvo1m0ouZpmaYE2wlUqmwqxGT1IHA461Tu/iX4jstN8OWcNlp99rF9pZ1B5QWMcuMYRQMYc5y3ZfQigZFovwgvodOtLbVxo959n8O3Olpu3SBLmSZnSRdycAK2N33gc4FQal8INYuBabp9OvQdKsrGdJrmWLyZIEC7o2WMllJG7HyHPcV02l+OfEmuX+txaTounCPTbSC4ZJ7lzK7zWnnLGoVSrfOQpO4ccjNafww8cyeO1vry3tFh0u3WCNJcnc87Rh5Ux6IWC+5oA7qiiigQUUUUAFFFFABRRRQAUUUUAFFFFABRVTU9QtdLs3ur+YQ26EBnIJAycdqzl8XeHWXcNc0zHvcp/jUucVo2awo1JrmjFtehuUVzsnjbw2hwNYtZD6RMZD+S5qjP46tri6Wx0CyutS1F1LpGyGBAP7xaQDj6A1LqwXU1jgsRL7DXqrL73oS+Pz5iaDaL9641a3GP9lSXP6LXV1zWj6FdyX8WreIrlbnUY8+TDFkQWuRg7B1Jx1Y10tEE7uT6hXlFRjSi72vd9Lvt+B5z8ZvHzeC9HihsAratehhCW5ESjq5Hc8jA9fpiuB+FHwz1HV2j8W63qNzbXkrG4syDukZj/y0kJ6qf7v8QPUA1m/HkKPi3pR1UFtOMVvkHp5XmHeP/Qq+jrmFpdPlgtJfszNEUikRQfLJGAQOnHpXrVJfV8PGMFrPd/ocK96V30PlzVPGfirxZ8U7rw/p1uLvTEdbS8sIZ/3EyRP+8fzCMqrHIJ7qQDnivpONQqKoUKAAML0HtWVpfw88O6VoMWl6dZm2ETeat3G2LjzcY80ydS3PfjHGMcVFYX93p9+ukeIHQ3Tf8et4q7Y7xR7dFkHdO/UcZA8to6oSvublFFFI0CiiigAooooAKKKKACiiorqeK1tpri4cJDEhkdz0VQMk/lQBS0zZd+NbiRTn+z7MRH03TNuI+oESn/gVdRXO+BbWWPRPtt2hS91KRr2ZW6ruxsQ/7qBF/Cuiq0c0nd3OU1SJtP8AGVvdKv8Ao+pwfZpCP4Zo9zofxUyD/gIrVpvizTZdU0OeK0YJfRET2rnosyHcmfYkYPsTVTRdQj1XSrW+hBVZkDFG6o3RlPuDkH3FSzWm9LF2iiikaBRRRQAUUUUAFFFFABVPVtQg0uwlu7neUTACRrud2JwqqO7EkAD1NWZpY4IXmnkWOKNSzu5wFA5JJ7Csjw7ZS65ex67qcbx2sZzplo4xtGCPPcf32BO0fwqfUnAlcmUrI8m+O/h3VW0TTfE2pSlLpZPJe0jbMdqjcqAe7ZGGbucY4Ar174W67L4j8B6TqNyc3LRmOVj/ABOhKlvxxn8a5f8AaPvYrb4eG3cjzLq6jRB34yxP6frV/wCAMDw/C/TC4I8x5pBn0MjAfyr05q+Ci30ehx3/AHjPRK5P4gsII9BvHIWO21WBpGJwFVtyEn2+YV1lQ3ltBeW0lvdwxzQSDa8ci5Vh7ivNnHmjY6sPVVKopvYmBBAIPFZmr+H9G1mSOTV9J0+/kjUqjXVskpQHqAWBwDWM3hvUdJw3hXUzBCvTT73MsH0U/fQfQke1Vr7xtcaHBu8S6DeWvO1ZbZ0njc9sHIIz6EVDq8vxqxssI6r/AHDUvLZ/c/0udRb6Vp1styttYWkIuQBOI4VUSgLtG7A+b5RjntxVKXwp4dl06HT5dB0l7CFi0Vs1nGYoyTklVxgEnrisuHxo80ayReGfETRtyG+yqMj6Fs1qaJrzapcvC2k6tY7U377uAIh5AwCCeeapVIvRETwlWmm5LbzRes9LsbF5nsLO2tJJlRZHgiVGYIu1MkDnauAM9BxVDwb4asfCWgxaVprTSQo7yNLOQ0kjuxYsxAAJ59OgFbdFWcwUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVWaws2bc1pblvUxjP8qs0UWuNSa2GxxpGMRoqj0UYrK8R6Fb65aosjPBdwtvtrqLiSB/UH09R3rXopOKasyoVJU5KcXZo53w5rc0t0+j63si1u3XLbeEuU7SR+o9R2Oa6KsnxBoVrrcEazmSG5hbfb3UJ2yQt6qf5joayLHxHcaVdLp3i8RW0xOINQX5be5HuT9x/9k/hWak4aS27/wCZ0ypLELnorXrH9V3XluvTU5L9oLwZc+IdDttU0uMy3mnBt8SjLSRHBOPUgjOPQmsj4WfGLTF0e00nxRK9rd26iJLtgWjkUcLuI5VscZPHGc17gpDKCpBBGQR3rz3xf8IvDXiS6lvDHNYXsmS8tqwAdvVlIIz9MZr06OIpyp+xrrRbNdDz5Rad4ncadqVjqcIl068truI87oJVcfoabrOl2ms6dLZX8fmQSYPBwyMOQykcqwOCCOQRXz/qnwO8RaM5u/DGsJcSpyoBa2l/AgkZ/EUnhP4x634aum0nxtZ3F0IW2NIw2XEf1BwH/HB9zVPAqa5sPLm8tmHtLfErHr+i3dxBdzaLqrl9QtUDpMQALqHOFlGO/Zh2PsRWzXH6j4p0LxLp1nrWgajDJe6ZKJmiJ2yiFiFmVkPONvPplVPauwrzpwcHaSsddOXMgoooqSwooooAKKKKACsPxEqajdadoRUuL6XzJwO0EZDPn2Y7E/4HW5WT4QiN9q+r61KODKbC29oomIYj6yb/AMFX0oRM3ZHWUUUVZzhXHWMQ0vxTqunhh5N3/wATGBP7pY7ZR/31hvrIa7GuW8XqLfWfDuoZxi5ezf8A3ZYyR/4/HHSZUHZmnRRRUnQFFFFABRRRQAUUVja9NdXFxa6PpkhivL3cZJwebaBcb5B/tchV/wBpgegNAN2IRbHxVqpifB0CxlxMOovJ1P8Aq/8Armh+96sMdFOe1rImn0fwjoEf2iaCw0y0QIpdsAD09WY/iSa8F8bfFfWfGF42g+C7WeK3uD5QdB/pE474x9xf1x1I5FdeHws6793bqzknU7kfxw1n/hMvHel+HdEkW4W2fyNyHKmd2Abn0UAfrX0Poemw6Po1lp1sP3NrCsK+4Axn8eteb/CL4VReFGTVdZZLjWiuEVeUtgRyAe7difwHqfVq1xdWDUaNJ+7H8WTBPdhRTZHWNGeRgiKMszHAA9Sa5AanqHiuZ4dBlex0ZSUk1Lb+8nPcQA8Af7Z/CuCU1HTqdNKjKpd7Jbt7L+uxe1jxIIr9tK0W3Oo6vjLRqcR24PRpX/hHt1NJovhkQ3q6prdwdS1jHyyuMRwD+7EnRR79TWpomkWWi2QtdPi2Jnc7E5eRj1Zm6kn1rQqVBvWZpKuoJwoaLq+r/wAl5L5thRRRWhyhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWN4i8RWmgfZ/tkN5L5+7b9ngaXG3Gc46dRWzXI+P/wDlw/7af+y0ARf8LF0n/nz1j/wBel/4WJpP/PprH/gDJ/hXK0U7AdWPiHpBOPsurj3NhJ/hT/8AhYGj/wDPHVP/AABl/wAK5GiiwHXf8LA0f/njqn/gDL/hUN3420C9tngu7PUJ4XGGjk0+RlP4Fa5eila402ndF7wZ400/S9Pn0q6GoyLZzMluwtJGYwE5j3cZBAyOewFdB/wsDR/+eOqf+AMv+FedykW/iWA9Fu4GQ/7yHI/RjWtWdLRcvb+vyOnF+9NVP5lf57P8Uzrx4/0c/wDLHU/xsZP8KxvEmp+DfEsHl63pN1dcYWRrCQSKP9lwMj8DWTRW0W4u8XZnLueY+Kvh9pa+ZceFr3UT1ItbuykB+gkAx+YH1qvo3j7xt4WZo74T3dtDtEkd6hfZuzt+fqM4OOccHivVqhgmi03X7K+lUNbz/wCg3QPKlHI2MwPo+B7B2rtWPk1y1oqS89/vJVPX3XYi8M/GfQNSCx6skulz+rgyRk+zAZH4gfWvR9O1Cz1O2W40+5huYGGQ8Thh+lcZ4l+FPhnWy0kdqdPuT/y0tMIM+6fd/ICvOb34TeKvDc7XvhbUxcMvTyXMEpHpgnB+maXssJW+CXI+z2+805qkN1c+g6K+fNO+LHirw3ci08V6a1zjj99GYJfqDjB/L8a9E8NfFjwzrW2Oa5Om3J48u7+Vfwf7v5kVlVwFamr2uu61LjWhLQ7+imxukqK8bK6MMqynII9RTq4zUa7BUZj0AyaXwlp7aX4a060kO6ZIg0rDvI3zOf8Avoms/wARSmDw/qco6payt+SE1v6aWOn2pk5cxLn64FOJlULFFFFUZBXM/EbevhSa5jUl7Se3uhhcnEcyM2P+AhhXTVznxGOPAut46/ZmoGty7RRRUHSFFFFABRRXMeM/G+jeEoM6lPuumGY7WL5pH98dh7nFVCEqj5Yq7E5KKuzpjXjmq/FnTNAvddn06L+0damuTbxswKxQwxjCjP8AEN29sL13dRxXEeIvHHiT4g3/APZenKbSwlz/AKPG2AyjGTI/ccjjp04Nb/hb4fWOlMtxqJW9uhyAV/dofYdz7n8q9KOFpYb3sQ7v+Vfqcs6rnpA5f7P4h8favFfeKLy8isXyyyi3eRUX0jjXgfXj3Jr2nwje+DfB9kIdI03UhMVxJcNYyNLJ9Wx09hge1VBRWNfFzrLlWkeyJjBLU6n/AIWLpP8Az56x/wCAL0f8LF0n/nz1j/wBeuWorlsWWPEnjPTtZ1HT7CSDVP7LG6e9h+yuHlA+4uOpTdkntwBW/F8QNGijSOKw1ZI0AVVXT3AAHQAYrgNL/wBI1vVLrqqFbZD/ALoy36mtisqaveXc68U+XlpLZJfe9X89bfI6n/hYuk/8+esf+AL0f8LE0n/nz1j/AMAXrlqSRgiM5BIUE4HWtbHIdV/wsXSf+fPWP/AF6P8AhYuk/wDPnrH/AIAvXkHhXWNa1bTIvENzd6fHpcolc2QjwyIu4D96WxuyozkYxnpUEXxGgNlqM8+nSq1mkMoWOQMJUkkCAqxA7n6e9ID3nw/4rsddvHtrSC/jkSMyE3Fs0a4BAxk9+RxXQV8/y+ONV0u31ldL0iWHVLbSZryVppoyLVQ+EYgbg5O3O0dj1rq4fiTNY3V7HcW91qU4udMsordPKjHm3MAf5WOOCeu48Z7CgD1WivNG+KRGiy3LaI0epQ6nLpcthJdru82NQx2FQTJwy/dXv6c07wd48n8VeM9JW0DQ6PfeH31D7PIql1mW5EX3hzjG4enegD0miiigAooooAKKKKACiiigArkfH/8Ay4f9tP8A2WuurkfH/wDy4f8AbT/2WgDkaKKKYBRRRQAUUUUAVNSsY76FVZmjljbfHKn3kb1H+FVLHUpI7hbHVAI7v/lnIBhJx6r6H1Fa1Q3lrDeW7Q3MYkjbqD29x6Gs5Rd+aO50060eX2dVXj+K9P1XXyepNRWIk9xozCO/cz6eSFS5P3o/QP6j/a/OtsHIBByPanGfN6kVqLp2d7p7Ndf+D5BUN7bpd2c9vL9yVCh9gRipqKsxOr8G6lJqvhuzuLkg3agw3H/XVCUf8ypP0NbdcX4BkWDVNbsgQN7R3ir/AL67D+sWfxrtKzZ0xd0VNS06y1S2NvqNpBdQHqkyBx+tec+Ivgt4f1BXfSpJ9MnPICnzI/8AvlufyIr1GitaWIqUfglYUoRluj5xm8NfED4eu0+kTzXFghyTat5sZHq0R6fXH411XgP4yxX91HYeKIYrSVvlW7j4jJ9HB+79c4+leyVwPxH+G9h4ui+0W5Sy1ZB8s4X5ZPZwOv16j36V3LF0sR7uIjr/ADIxdKUNYP5HTeLCJPCOsmMhg1jMVIOQf3ZrqLHmyt8f881/lXyrba94n+HJudA122ebTZ4nRYXbK4YEbon/AB6foDX0Z4E8TaV4l0O3l0m8Sdoo0SaPo8bY6Mp5H16HtWFfCTo+8tYvqiXUU/U6SiiiuYArmviL8/hWe3B+a6nt7YD13zIp/QmulrlfFjfa/EHh/TgMqksl/L7LGu1f/H5FP/AaGOKuzUoooqDpCoL68t7C0lur2aOC3iXc8kjYVR9a5vx3450rwfag3rma9kXdDaRn539yf4R7n8M14nFaeL/i1qv2iUmDSkfAZsrBCPRR/G36+pFdmHwbqL2lR8se/wDkZTqqL5VqzofG3xhur24/s3wVFJl22C6Me6SQ9MRp2+p59hSeDfhDeatMdU8b3E4aU7zbeZmV/d37fQc+4r03wT4G0fwjb4sIfNvGGJLuXmRvYf3R7D8c1oeM9TfSPC+pXkOftCRFYcf89G+VP/HiK1njI0l7PCqy79WQqTl71Rnn+l2tqL68uLG3jt7ONzaWcUYwFhjJBb3LsGYk8kbfStSoLC2FnY29spJWGNYwT3wMZqeuJtvVkhRRTJ5o7eF5ZnVI0GWZjgAUN2Gk27IfWPcahPeXD2ujhSUOJbphlI/Yf3mqM+fruAvm22l9z917j+qr+prZt4Y7eFIoEWONBhVUYArK7qbaI6+WGG+PWfbovXu/L7+xDp1nHYWqwRFm5LMzHJZickmrNFFaJJKyOWc5Tk5Sd2wqC+u4LCzmuruQR28Kl5HIJ2qOp4qesjxjZz6j4W1Wzs4/MuZ7Z440yBuYjgZPFMkzNO8OeF57+6lsrJTLtJlXMgjxKnOFJ2cqxBwO9TxeCdAjgmhWycxzRpE4e5lYlUYMoyWyACB0+nSuO17TdVsNP1ae9Yxae02nkxtdLGJokjVZYw2cLluOcZqlpdhqOtaDL9g095dOk1eaQIZlLxw+WoTyyzBGXORnn1GaQz2TS/B+h+JtYmOs2bTk2jQsUnki3oWHytsYbhznBzzzXaHwN4dN0bk6d++NxbXe7z5P9bbLshbG7HyqMY6HvmvB/D3grxBq2mR2d9b3MtzB4fu41QXu3/S937gEhwG/h65UYGeldPP4D8XxaXrtvphuYTfWenSSLLfljczpk3Kbi5KluhPCnpnFAHpt34A8NXTu82nMJXvZNRMkdzKjieRQrsGVgQGVQCoO046UaJ4b8LeG9V06LTYoLTUI7KS0tImumZzb+YJHCqzEsA5BLYJGcZxXm2h+ANamvtBtdTstTj0Fb68lu7ea+RPLje3UIoEMhOwyDhQT3yACaPDfgTXbPUfAF/rGlXF5Npq3Ntdf6eu+3X7QWgc/PhlVTnCknHBBwBQI9yooooAKKKKACiiigAooooAK5/xZo17q/wBl+w3FvD5W/d5yM2c4xjBHoa6CigDz7/hDdZ/6CGn/APfh/wD4qj/hDdZ/5/8ATv8Avw//AMVXoNFAHn3/AAhus/8AP/p3/fh//iqP+EN1n/oIaf8A9+H/APiq9BooA8+/4Q3Wf+f/AE7/AL8P/wDFUf8ACG6z/wA/+nf9+H/+Kr0GigDz7/hDdZ/6CGn/APfh/wD4qj/hDdZ/5/8ATv8Avw//AMVXoNFAHnkvgnVpY2jkvdNdGGGVoHII/wC+qw73wjr/AIcsS9nJDqNoGyYo42MkC/7K7suPbOa9foqZQvr1N6Vd07xavF7p/wBaPzR5Zo+kz6vAkun65pE+4Z2rE4YeoKlsg+xrT/4Q3WP+f/T/APvy/wD8VS+MbrwXHcyC8s4b7Vy3+qsEzc7vUupGz6swFcZPP4rvbH7O2rSW1oZCywPKZJQmOEeZQrH8MfU1PNNbq/oaezo1Pgny+Uv81+qRvaXAuj/Ei3sbnULK4vrjT5Q0NuCGjCujKWBJxnL4zjoa76vF9J07UrDX9FispNPtpZZ5VR44GI3GFyWfLZYkL3Oc4r0L+yPEcn+u8TBB6Q2CD9STUub/AJX+H+ZrDDwS1qR/8m/yOmorD07Rbu2u457nXdRu9mf3T+WqNx3AXP61uU0291YmpGMXaMr/AH/qFFFFUZmfrmjadrtg9lq1pHc27fwuOQfUEcg+4r54uPCHiPwW0viTwzdPLFZXU0ExiHzwhHIHmL0ZSu1s9OeQOtfS9Y1lJ/ZPi2SJwfsOsgFT2W5RcEH/AH41H4xn1rqw2LnQdlrF7roY1qakr9TnPhd8WrLxW4sNXWDT9W4Ea7zsuP8Adz0Of4cn2zzj1KvF/il8HbfUkfVPCMUdrqC5eS0U7Y5u+V7K3t0PtWN8M/izd6Rdr4f8decnlt5SXcwIkhP92UHkj/a6jvkcjqqYaFaPtcN811RzqTi7SPoGuR0e7bV9T1LVNq/ZvMNnaMOd0cZIZ8/7TlvwVTU/jDUpHtLbS9JuQt/qfyxyxnJih6yTD6KcA/3mWrVjaQWNlBaWkYjt4EEcaDoqgYArzGdNOPUnriPib49tvBtgqRhLjVZh+5tyeFH99sdv5/mRe+IfjC08H6G91MVkvJAVtoM8yP6n/ZHUn/GvH/hp4QvfHeuzeI/FJknsd+795x9pcfwj/YHt9PXHbhcPFxdet8C/HyFUqO/JDcf8PvAd/wCOr9vEfiyaZrOV9wV8h7n6H+FB04+gx1r6As7WCytYra0iSG3iUIkaDCqB2AqSONIo1jiRUjQBVVRgKB0AFOrLE4qWIlrolsuxVOmoIaHUnhh+dct8QbabUbfSNMtnRJLvUIhucEqNgMvIBH9yrUngvw7JIzvpUG9iSSMjJ/OuP8b+HdIsdU0CC0sljSeaUyAOx3BYiQOT6kVxpzvsvv8A+AdUo4e3xS/8BX/yR0Z8Ha2OuoaYP+2D/wDxVUNU0a70q1kuL/XNGhiQZOY3JPsBuyT7CucsdJtNKnZrjSotZsGYs0UjlbiMHsjZCuB2VsH/AGu1eh+ErHwZflbjQ7CxFzFhjHJDtnhPurfMpz3/ACNU3U7L+vkYqOGWrlJ/JL8eZ/kcMZrlk8uFp5L48paf2VMruD0PLYCn1JrVi8A69qQt7nVbuwhKjcLLYzordixB5Pt0r1eijkb+J3H9ZjBfuY8r73u/ltb8/M8+/wCEN1n/AJ/9O/78P/8AFUf8IbrP/P8A6d/34f8A+Kr0GitDkPPv+EN1n/n/ANP/AO/D/wDxVH/CG6z/AM/+n/8Afh//AIqvQaKAPPv+EN1n/n/07/vw/wD8VR/whus/8/8Ap/8A34f/AOKr0GigDz7/AIQ3Wf8AoIaf/wB+H/8AiqP+EN1n/n/07/vw/wD8VXoNFAHLeFtA1DStQknvbq1mjaIoFijZSDkHOSTxwa6miigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAornvEfi/S9Dl+zSPJd6iRlbK1XfLj1bsg92IFcTqOua/raOtxcDSbR+lvZNmXHo83/xAXHqaAO18QeMNK0Wf7K7vd6icEWdqA8oHq3ICD3YgVxGuatrXiEmO4nbS9Oz/AMe1nIfNlH+3LgEf7qY/3jVWys7exh8q0hSJM5IUfePqT1J9zS3d1BZwNPdzRwwr1eRgop2ASxsrawtxBZwpDEOdqjGT6n1PuaL28t7KISXMgRWYKowSzseiqByxPoOataRpOta8Ueytv7P09uftd6hDuP8ApnFwfxfb64Ndx4e8I6ZolwbtFlu9QIIN5dNvkAPZeAEHsoHvmgDz2xsNWbxd4YvL63+wWLSzNFby/wCvkPkP8zjogGemc884xg+m1l+Ih5vjPQEH/LK3u5z/AOQkH/oZrUqGb09gorM13VP7MtoxDC11fXD+Ta2ynBmkIzjPZQASW7AE1V8NXGoJNf6drlxFNqVvIJSYo9imKQZUqPQEOvr8nNIq/Q3aKKKBhWZ4kspb/RriK0fy7xQJbd/7sqEMh+m4DPtmtOigCxoWox6vo1lqEIKpcwrLtPVSRyp9wePwri/ir8ONP8Y2T3URS01mFP3dzjAcD+GT1Hv1H6VveAjt0i8t1GEt9Quo0HovmswH/j2K2tVVn0y8VPvNC4H12mtqdWVKSnB2ZytJ6M+YPhV40bwlrf2HxHHItrcRpGk8oJe3Tlkxn/lmdxOB65r6C1rWbHRtFn1W+nVbOJN+9TndnoF9SeMfWuB8Z+CLbxj4G0y6sERdVgso2tnHHmLsB8s+x7eh/GvEbS+1/wATQaT4SjleWKKYrBE3GCf7x9FGcegzXpqhTx1qqfK18X+YueVH3d+x0+kWGpfFvx3Nf3geLSoWHmc8RRZ+WNf9o8/qa+kLO2gsrSK2tIkht4VCRxoMBVHQCsnwb4ctfC2gW+mWQzsG6SQjBlc9WP8AnoAK3K4cXifbSUYaRWyNqVPlV3uwqrYahZ6jE0lhdwXUaMUZoZA4DDqCR3rL1kzaxqC+H7FnjWRPMv7hODBAcjap7O+CB6AM3YZf4j0iDQ0j1zR4Ut/sUax3cMYwk1qvXI/vRjLKfQFehrlsU5pOxt1xXxCtbq41Tw21hALicTzL5W8IWHksTgnjPy8A4HuK7NHWRFdGDIwyGByCPWsfXT5eseGZf7uo7P8AvqCZf6ikhy2OJstQgu3kiQvHcxcS28ylJYj6Mh5H16Htmi8sYrp45SZIbmLmK4gcxyxn/ZYcj6dD3zXqGveHdM11F/tC2Vp4xiK4T5Jov91xyPp0PcGuG1vwzrejEzWIbWrADlAFS6j98cLJ+G0+xqznH6R4x1bSFMWuwvq1ov3bu2QC4Uf7cYwG+qc/7Nd9pGr6frFsLjS7yG6iPUxtkqfQjqD7HBFeUWN/b3ofyHPmRnbJE6lJIz6MpwVP1FNNkItQGoafNLY6iBj7RbkAuPR1PyuPZgfbFAHs9FedaV49udPIh8V26+T21KzRjGB/01j5ZPqNy+u2u/s7qC9to7mzmint5BuSWJwysPUEcGgCaiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKz9e1IaRpNxfG2nujEBiGHG9yWCgDJAHJ5JPAzXm2qa1r+u/Lc3P9k2RHNtYyHzW9nm4I+iBfqaAO413xfpOjyy27ytdaggBNnajzJeemR0XPqxArhtS1nX9eJF3cf2TYn/l0spD5rD/AG5uD+CBfqarWVnb2MAhtIUijznCjqe5J7n3NLd3dvZxh7mVYwTtXPVj6AdSfYc07AJaWlvZoy2sMcQY7m2jlj6k9z7mi9vLexhM15PHDHnG52xk+g9T7Vf03Qdd1lS0MA0q1JGJr1CZWHqsQII/4GQfauy0DwfpWkTLdeW15qI/5fLoh5B/u8YQeygUAcLp+la9rkmyws202073t/GQT/1zhyGb6ttH1rttA8F6XpMiXEyvqOoKdwu7zDup/wBgY2x/8BA98101FIAooooA5S4QzePLiXOUtdPjjHs0kjs36IlaUsiQxPLM6pGilmZjgKBySTWL4XmOoNqer5zFf3TNB/1xQCND9G2Fv+BUviUfbZdP0RQG/tKXbMD0Fug3S/mMJ/wOoerOhe7EseD7eTUJpPEN6rKbldljC3Hk2+eGx2aThj7bR2NWvFWkXFz5OpaQEGsWYPlhjtW4jP3oXPocZB/hYA+oPQAAAADAFFWYXd7nOaRqVvqlmLi2LDDFJI3GHicfeRx2YHgirtUtc0KYagdY0Nki1EgLcQOdsV4g6Bz/AAuP4XwSOhyOmdF4psI2EOsF9Hu+8N/iIE/7L/cce6k1LRtGaZvUyeWOCCSaZ1jijUu7scBQBkk1izeLNGD+Xa3i6hcH7sFgDcyH8Ezj6nAqSPRr/X3ifX4ktNLUh/7NDB3mIPHnMONo4OxcgnqxHFKw3JIueAI3HhqK5mjaOS+mmvSrDBCySM6g++0rXR0VDe3MVlaT3Vy4jghRpJHPRVAyT+VWl0OdnhnxM8Rz+C/Dd54YgMkd5JIy2cq5/wCPNySCD2K8x/8AAc+leSjTtV8GXXh3W50MT3GLqFeh2q3Q/UY/Bq67w1YXHxc+KF3fagZYtPjzK+zBMUY4jjGQRk/T+8a9J+KHw+1rXPDLompwX8tlmeBHtAkzYHKBlYLyP9nqBXt05wwbjQfX4vmZO9S8u2x32n3kOoWFveWrh4J41kjYd1IyKztV1SZrk6XoaR3OsMBkNkx2yn/lpKR0HovVug4yR5P8Dtbutetx4XutXksFtEZokgiAmmTJLL5jZ27c9lzg8EYr3rSNLstItPs2nW6wRbizYyWdj1ZmPLMe5JJNeTiKDo1HBnQqvMrog8O6NDoth5KSPPPI3m3FzL9+eQ9Wb8gAOgAAHArTdVdWV1DKwwQRkEUuaKyIOL8Lq1g1/oUhJOmy7YCTkm3f5ovyGU/7ZmneLPkg0uc8CHU7RifQNKqH9HqzrsaWnjDSrzJBvIJLJh2Yr+9T8gJf++qqeOkZvCOpyR/fgj+0r9YyJB/6DU9TdaxO0opsUiyxpIhyrAMD6g06qMDE1/wvpGusJL+1AulXal1CximQezrg49jx7Vwuq+Hde0Ni6I2t6cD/AKyFQt1GP9qMcSfVcH/Zr1WigDxuzvbe88wW8oZom2yIch429GU8qfYio4rWewuPtOhXsumXGdxWLmGQ998R+Vs+ow3vXpniDwvpmuMst1E0V6g2pd27bJkHpu/iH+ywI9q4nVdA1vRkMhi/te0U8y2qYmUerRfxf8AOf9kUAbOj+PolXyvE9uumSqObpW32r++7qn0YAe5rt4ZI5oklhdZI3AZXU5DA9CD3FePWl3b30BktpUmjyVOOx7gjsfY0aaLzQpDJ4duhaITue0dd9s5/3MjYfdCPfNAHsdFcXp3j+xEog1+JtKkJws7tutnP/XT+H6OF9s12UbpIivGyujDIZTkEUAOooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDI8Wf8i/df8A/9DFeX6hqNpp6K13MqFzhE5Z3Poqjlj7AV6xrunf2tpU1kbma2Eu3MsO3eoDAnG4Ec4x071V0HwzpGhBm06zRZ3+/cSEyTSf7ztlj9M4oA4DRtB17Xisvlf2Lpx58y4TdcyD/Zj6J9Wyf9mu60HwnpOizm5t4GmviMG7uW8yXHoGP3R7Lge1b1FABRRRQAUUUUAFc749klTw8YoZGiW6uILSWRDhljklVG2nscMRntnNdFVLWdNh1axNpcNIsZkjlzGQDlJFcdQeMqM+1AIpW0EVtbxQW6LHDEoREUYCqBgAfhWdpCi58d38rHIsrCKJB6GV3Zv0jjro/skfq351XsdJgstSvb2J5TLdiMSBiNo2AgY49zUpGsppqyNCiiiqMgprokilZFVlPUMMinUUAMiijiXbEiovoowKfRRQAV5X+0Xrcul+BBZ27FX1GYQMR/zzALN+eAPoTXqlfN/wC0Tqz634y0zw5YZke1wpVe80pGB+W3/vo12YCnz1432WpFR2iek/AXw9HongG1uSo+1al/pUrf7J+4PoF5+pNej1T0WwTS9HsbCL/V2sCQr7hVA/pVyuetUdSo5vqVFWVj5i+LFg3gP4sWWuaaDFBcOt4qoMAMGxKv0PX/AIHX0zbzJcQRzQsGjkUOreoIyDXj/wC07p3n+EtNv1UFrW72E+iupz+qrXafCHUP7S+G+gzs25ktxAx94yU/9lrtxD9rhqdR7rQiOkmjsKKKK840Oc8bW088OkSWsUkslvqUEmI1LEKSUYnHYK7ZNW7m0+020sE0TNFKhRxjqCMEVsUUmi4zsrHP+C7mb+yIdOvLe7hvNPQW8jTQsqyBflV1cjawYAHgkjPOK6CiimQFFFFABRRRQBzuveENL1i4+1tG9pqOMfa7UhJCPRuMOPZgfbFcLq+maz4d3NqUB1DT15+3WcZLIP8AppEMkf7y7h67a9cooA8dgmt722WSCSOe3kHDKQysKl8L2L6VrNr/AGNdTWUEs6LLbKd0LqWGQEPCkjPK4rtdd8F6dqEsl1ZbtM1F+WuLYACQ/wDTRPuv9Tz6EVy9pY6vo+tWKavZboTcxIl5aZeJiWAG5fvR/jlf9o0AeoUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBkeLNdtvDXh6+1a8P7q2jLBc4Lt0VR7k4FeEfAvRbnxX43v/F2r/OtvK0ikjh526Y9lB/D5af8AH3xFP4i8TWXhHRC84hlAlSM5Elw3AX/gIP5k+le2eBfDkPhXwtY6TDhmhTMrgffkPLN+fT2Ar0l/s2Gv9qf5GXxS8kb9FFFeaanB/HKzF58MNZGPmiEcw/4C6k/pmsX9my7+0fD6SAnm2vJEx6AhW/8AZjXd+N7Mah4O1u1Iz5tlMoA9dhx+uK8f/Za1AbNe05jyDFcIPzVv/Za9Cn72DmuzTM3pNHvdFFFeeaBRRRQAUUUUAFFFFABXMa/4ofSvG/hTQFtVlTW/te6YvgxeTEHGBjnOcdRiunrnvFXhOz8R3WmXkl1e2Oo6a7va3lm6rJHvXa4+ZWUhhgHIPSgDi9H+LbXl7ottLoNyx1K+vLTdbMZPLEGcMBt+YnuMjaOea2R8VvDJ1aexEt1+788LP5P7qRoVLSKpznICtjIAOOCai/4QTw3pMOiW8OrXWn3WjPPfxT/aoxM4cYmeTepBUg4JAGOxFFv8MdCM13c2F/fx2V8JpDbwvE0X75WDMjFC+PnJA3bc9qALS/EvRpbGwuLaz1md9QJ+x262LrLcKIxIzoGxuQKwywOPTNRv8U/DrT6bDYm9v5b63W7jW1g3ERsxUEgkHOQRtGTx0q7eeA9Pn0vw/aQXupWc+hQC3sr22lVZ1TyxGwJKlTuVRn5eoyMVkaj8IfDt/aabZSS36adYRJFHaq8ZUhW3Z3MhdSxPJRlzQBqN8RNFi8Wjw7drd2t6zSKkk8YWN9ilic5yBgEgkAHHFVB8UdE/s+PUHs9ZTTpmRbe6axfZcbnCApjk5JHGASOgNMt/hVokHiEaqLrUnxdzXotXeMw75VKvn5N5BDHgscU6L4YadHZWlidY12TTrOaKa1tJLhGjg8uQOqr8mSMgD5iSBwCKAJNZ+Jui6LLYjVLXVbSO7VGEk9qY9m9io3KxD5yOQFOO9afgjxDceIJfEa3MUUQ0zV5tOj8vPzIioQzZPX5z0rJ8V/DDR/Eur3uoXd7qdvJepClxHbyR7H8ptyH5kYjkDIBAPpnmuk8OeHrTQH1ZrOSdzqd/JqE3msDtkcKCFwBhflHXJ680AbFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFYnjbXD4a8JatrIg89rK3eZYs43EDgE9hnGfauPh8Ta94a8JHxP4t1Cw1KyuLaKWK0sLUxOksjIERXLkMnz8k4P1oA9LorzO3+KvnWlsf+Edv2v59Q/s5LaORMOxjLqyO+1SpxjnGDVweOtR1BNYGl6BOINNL211dPcR/uLhYg7KE53hSygkHntkUAegUV4+/xal0Twh4fvtUsRqVzc6ZFfXbQzKkihuCwiAPHfJ2r2Brbl+J0R1cQ22j3E2mf2tDohvjMq/6TJjIEZ52qGGT37UAei1xvxV8Xx+DvCdxdo6/2hNmG0Q85c/xY9FHP5DvWZ4U+KNt4k8Swaba6VdrZ3LTpb3mQwJizneoHyA7WwcnOO2a6Txn4P0fxhYJbazbljGSYpoztkiJxnaffHQ5FaUXBTTqbCle2h5L+zn4SkmnufFuqozu5ZLRpOSxJPmSf+yg/wC9XvdVtOsrfTrC3srKJYraBBHGi9FUDAqzV4mu69Rzf9IUY8qsFFFFYFAQGBBGQeCDXyxY3Mnwi+LN2by3mk05hIqiPrJA5yhXPBIIAPuDX1PWT4g8OaP4hhjj1rTre8WM5QyLyv0PUV1YXEKlzRmrxluRON9jxOL9oK4OsqZdFiXSS2GCyEzAeoPCk+2Px717to+pWusaXbahp8oltblBJG+MZB9uxrD1XwF4a1PRYdKm0q3is4ZBLGsC+WVbvyOeRwfX8q6O2gitbeK3to0ihiUIiIMKqjgAD0oxE6E0vZRswipLdktFFFcpYUUUUAFFFFABRRRQB5V8SrHVX8X3N7pdldzFPC2oRRSxQM4884KIOCCxI4XqfSuH8eeIfEujaZcvd3ut2E8GjWH9mraxlYvOYAT+fgcPngK2PYV9G1m3mgaPe6lFqN7pOn3GoRACO5ltkeVAOmHIyOp70AeTanfeL/8AhacDWcGvwaeusR28sRjlltpLQp80oYL5arntywPUjpWRZ2njy606xludS8WRTXenalJcRqm3ypYpG+zqP3eVLAD/AGmHAOOK+gqKAPBPEl18QZxosjTa3Zq+jWsqSWdnJJi82gzCaNFJ3Z42uAoGehzWiq+NG1Yam114gBTxalmLIRH7OdPbZuk27clBlvnyQMeuTXtVFAHmfwR0u70aDxJZagusLOmpTMPtsZEToZHKyRNtAcsOWIJ7dK9MoooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAjureG6tpbe5iSWCZDHJG4yrqRggjuCK5Ow+GnhGxtbu2g0dDb3UXkyxSzyyrs3BtqhmO0bgD8uMED0rsKKAOas/A3h+0a0aO0nd7W4F3C815PMySBSoOXckgAkYPHPSi88D+HrvVptSmsD9rnO6Ux3EqJI23buZFYKzY7kZrpaKAONvvhl4Svra3guNKYwwWi2Kql1MmYFOVRtrjeAem7JrGvvhVb3fjWDW/t6QWkV7Dfi0ghdS8kQG0sxlKHkckRhj0zXpdFAHO6b4L0HTNYOp2Fk9vdGR5dqXMoiDuCGYRbvLBIJ52966KiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transabdominal cerclage tied at the level of the insertion of the uterosacral ligaments.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_44_27328=[""].join("\n");
var outline_f26_44_27328=null;
var title_f26_44_27329="Nail map paper and cassette";
var content_f26_44_27329=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F83981&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F83981&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Nail map paper and cassette",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 357px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_44_27329=[""].join("\n");
var outline_f26_44_27329=null;
var title_f26_44_27330="Labial hypertrophy";
var content_f26_44_27330=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F51816&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F51816&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hypertrophy of the labia minora",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bilateral labia minor hypertrophy fully extended.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     <p>",
"      Reproduced with permission from: Laufer MR. Structural abnormalities of the female reproductive tract. In: Pediatric and adolescent gynecology, 6th ed, Emans SJ, Laufer MR, Goldstein DP (Eds). Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"     </p>",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_44_27330=[""].join("\n");
var outline_f26_44_27330=null;
var title_f26_44_27331="Congenital hernia of the diaphragm PI";
var content_f26_44_27331=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F82792&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F82792&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 505px\">",
"   <div class=\"ttl\">",
"    Congenital hernia of the diaphragm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 485px; height: 627px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The baby in picture A is a normal newborn baby. The baby in picture B has a congenital hernia of the diaphragm. In this condition, the diaphragm (the layer of muscle that separates the organs in the chest from the organs in the belly) has a hole in it. Because of this, organs in the belly move through the hole into the chest.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_44_27331=[""].join("\n");
var outline_f26_44_27331=null;
var title_f26_44_27332="Ear infections PI";
var content_f26_44_27332=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F54739&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F54739&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 494px\">",
"   <div class=\"ttl\">",
"    Ear infection (otitis media)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 474px; height: 327px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The ear on the left is normal and does not have an infection. The ear on the right shows what an infection can look like. The infected fluid in the middle ear causes the eardrum to bulge. Normally, fluid in the middle ear drains into the throat through a tube called the \"eustachian tube.\" But during an infection, swelling blocks off the tube, so fluid builds up.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_44_27332=[""].join("\n");
var outline_f26_44_27332=null;
var title_f26_44_27333="Cefpodoxime: Drug information";
var content_f26_44_27333=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cefpodoxime: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?11/6/11364?source=see_link\">",
"    see \"Cefpodoxime: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/18/25892?source=see_link\">",
"    see \"Cefpodoxime: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F147808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Cephalosporin (Third Generation)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F147776\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute community-acquired pneumonia and bacterial exacerbations of chronic bronchitis:",
"     </b>",
"     Oral: 200 mg every 12 hours for 14 days and 10 days, respectively",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute maxillary sinusitis:",
"     </b>",
"     Oral: 200 mg every 12 hours for 10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pharyngitis/tonsillitis:",
"     </b>",
"     Oral: 100 mg every 12 hours for 5-10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Skin and skin structure:",
"     </b>",
"     Oral: 400 mg every 12 hours for 7-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Uncomplicated gonorrhea (male and female) and rectal gonococcal infections (female):",
"     </b>",
"     Oral: 200 mg as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Uncomplicated urinary tract infection:",
"     </b>",
"     Oral: 100 mg every 12 hours for 7 days",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F147795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/18/25892?source=see_link\">",
"      see \"Cefpodoxime: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Acute bacterial rhinosinusitis (unlabeled use):",
"     </b>",
"     Children: Oral: 10 mg/kg/day divided every 12 hours (maximum: 200 mg/dose) with concomitant clindamycin for 10-14 days.",
"     <b>",
"      Note:",
"     </b>",
"     Recommended in patients with non-type I penicillin allergy, after failure of initial therapy or in patients at risk for antibiotic resistance (eg, daycare attendance, age &lt;2 years, recent hospitalization, antibiotic use within the past month) (Chow, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute maxillary sinusitis:",
"     </b>",
"     Children 2 months to 12 years: Oral: 10 mg/kg/day divided every 12 hours for 10 days (maximum: 200 mg/dose)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute otitis media:",
"     </b>",
"     Children: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 months to 12 years: 10 mg/kg/day divided every 12 hours for 5 days (maximum: 200 mg/dose)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &ge;12 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pharyngitis/tonsillitis:",
"     </b>",
"     Children: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 months to 12 years: 10 mg/kg/day in 2 divided doses for 5-10 days (maximum: 100 mg/dose)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F147777\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F147778\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Administer every 24 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hemodialysis: Dose 3 times/week following dialysis.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F147779\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dose adjustment is not necessary in patients with cirrhosis.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F147748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Granules for suspension, oral: 50 mg/5 mL (50 mL, 100 mL); 100 mg/5 mL (50 mL, 100 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 100 mg, 200 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F147732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F802618\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer around-the-clock to promote less variation in peak and trough serum levels.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F147751\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of susceptible acute, community-acquired pneumonia caused by",
"     <i>",
"      S. pneumoniae",
"     </i>",
"     or nonbeta-lactamase producing",
"     <i>",
"      H. influenzae",
"     </i>",
"     ; acute uncomplicated gonorrhea caused by",
"     <i>",
"      N. gonorrhoeae",
"     </i>",
"     ; uncomplicated skin and skin structure infections caused by",
"     <i>",
"      S. aureus",
"     </i>",
"     or",
"     <i>",
"      S. pyogenes",
"     </i>",
"     ; acute otitis media caused by",
"     <i>",
"      S. pneumoniae",
"     </i>",
"     ,",
"     <i>",
"      H. influenzae",
"     </i>",
"     , or",
"     <i>",
"      M. catarrhalis",
"     </i>",
"     ; pharyngitis or tonsillitis; and uncomplicated urinary tract infections caused by",
"     <i>",
"      E. coli",
"     </i>",
"     ,",
"     <i>",
"      Klebsiella",
"     </i>",
"     , and",
"     <i>",
"      Proteus",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F14470554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acute bacterial rhinosinusitis (ABRS) (pediatric) in combination with clindamycin",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F147815\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Vantin may be confused with Ventolin&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F147806\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Diaper rash (12.1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea in infants and toddlers (15.4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (1.1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (1.4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (7.2%), nausea (3.8%), abdominal pain (1.6%), vomiting (1.1% to 2.1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Vaginal infection (3.1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Anaphylaxis, anxiety, appetite decreased, chest pain, cough, dizziness, epistaxis, eye itching, fatigue, fever, flatulence, flushing, fungal skin infection, hypotension, insomnia, malaise, nightmares, pruritus, pseudomembranous colitis, purpuric nephritis, salivation decreased, taste alteration, tinnitus, vaginal candidiasis, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Reactions reported with other cephalosporins: Agranulocytosis, aplastic anemia, cholestasis, colitis, erythema multiforme, hemolytic anemia, hemorrhage, interstitial nephritis, toxic nephropathy, pancytopenia, renal dysfunction, seizure, serum-sickness reactions, Stevens-Johnson syndrome, superinfection, toxic epidermal necrolysis, urticaria, vaginitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F147754\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to cefpodoxime, any component of the formulation, or other cephalosporins",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F147736\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Penicillin allergy: Use with caution in patients with a history of penicillin allergy, especially IgE-mediated reactions (eg, anaphylaxis, angioedema, urticaria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; modify dosage in severe impairment.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F147741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of Cefpodoxime.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     H2-Antagonists: May decrease the absorption of Cefpodoxime. Separate oral doses by at least 2 hours.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Cephalosporins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F147767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Food and/or low gastric pH delays absorption and may increase serum levels. Management: Take with or without food at regular intervals on an around-the-clock schedule to promote less variation in peak and trough serum levels.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F147744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5951646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic events were not observed in animal reproduction studies. An increase in most types of birth defects was not found following first trimester exposure to cephalosporins.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F147783\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F147757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cefpodoxime is excreted in breast milk. The manufacturer recommends discontinuing nursing or discontinuing the medication in breast-feeding women. Nondose-related effects could include modification of bowel flora.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F147758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F147756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension (reconstituted)",
"     </b>",
"     (Cefpodoxime Proxetil Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg/5 mL (50 mL): $28.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg/5 mL (50 mL): $54.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Cefpodoxime Proxetil Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (20): $99.62",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (20): $128.25",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F147746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor renal function. Observe for signs and symptoms of anaphylaxis during first dose.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F147759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Banadoz (ID);",
"     </li>",
"     <li>",
"      Banan (CL, HK, JP, KP, TH);",
"     </li>",
"     <li>",
"      Banan Dry Syrup (KP);",
"     </li>",
"     <li>",
"      Biocef (AT);",
"     </li>",
"     <li>",
"      Cefadox (PH);",
"     </li>",
"     <li>",
"      Cefdoxime (KP);",
"     </li>",
"     <li>",
"      Cefirax (EC, PE);",
"     </li>",
"     <li>",
"      Cefodox (AE, BH, CY, EG, IE, IL, IQ, IR, IT, JO, KW, LB, LU, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Cefpobact (SE);",
"     </li>",
"     <li>",
"      Cepodem (IN, ZA);",
"     </li>",
"     <li>",
"      Orelox (BB, BM, BS, BZ, CH, CZ, DE, FI, FR, GB, GR, GY, IT, JM, LU, MX, NL, NO, PK, PL, PT, SR, TT);",
"     </li>",
"     <li>",
"      Otreon (AT, ES, IT);",
"     </li>",
"     <li>",
"      Podomexef (CH, DE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F147735\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F147753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid and well absorbed (50%), acid stable; enhanced in the presence of food or low gastric pH",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Good tissue penetration, including lung and tonsils; penetrates into pleural fluid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 18% to 23%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: De-esterified in GI tract to active metabolite, cefpodoxime",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 2.2 hours; prolonged with renal impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: Within 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (80% as unchanged drug) in 24 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Adam D, Bergogne-Berezin E, and Jones RN, &ldquo;Symposium on Cefpodoxime Proxetil: A New Third Generation Oral Cephalosporin,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1991, 42(Suppl 3):1-66.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Thoracic Society, &ldquo;Guidelines for the Initial Management of Adults With Community-Acquired Pneumonia: Diagnosis, Assessment of Severity, and Initial Antimicrobial Therapy,&rdquo;",
"      <i>",
"       Am Rev Respir Dis",
"      </i>",
"      , 1993, 148(5):1418-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/44/27333/abstract-text/8239186/pubmed\" id=\"8239186\" target=\"_blank\">",
"        8239186",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Backhouse C, Wade A, Williamson P, et al, &ldquo;Multiple Dose Pharmacokinetics of Cefpodoxime in Young Adult and Elderly Patients,&rdquo;",
"      <i>",
"       J Antimicrob Chemother",
"      </i>",
"      , 1990, 26(Supp E):29-34.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Borin MT, &ldquo;A Review of the Pharmacokinetics of Cefpodoxime Proxetil,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1991, 42(Suppl 3):13-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/44/27333/abstract-text/1726203/pubmed\" id=\"1726203\" target=\"_blank\">",
"        1726203",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bradley JS, Byington CL, Shah SS, et al.  &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;,",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2011, 53(7):e25-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/44/27333/abstract-text/21880587/pubmed\" id=\"21880587\" target=\"_blank\">",
"        21880587",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cohen R, &ldquo;Clinical Experience With Cefpodoxime Proxetil in Acute Otitis Media,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1995, 14(Suppl 4):12-8.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chow AW, Benninger MS, Brook I, et al, &ldquo;IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2012, 54(8):e72-112.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/44/27333/abstract-text/22438350/pubmed\" id=\"22438350\" target=\"_blank\">",
"        22438350",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fujii R, &ldquo;Clinical Trials of Cefpodoxime Proxetil Suspension in Pediatrics,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1991, 42(Suppl 3):57-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/44/27333/abstract-text/1726209/pubmed\" id=\"1726209\" target=\"_blank\">",
"        1726209",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Marshall WF and Blair JE, &ldquo;The Cephalosporins,&rdquo;",
"      <i>",
"       Mayo Clin Proc",
"      </i>",
"      , 1999, 74(2):187-95.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/44/27333/abstract-text/10069359/pubmed\" id=\"10069359\" target=\"_blank\">",
"        10069359",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mendelman PM, Del-Beccaro MA, McLinn SE, et al, &ldquo;Cefpodoxime Proxetil Compared With Amoxicillin-Clavulanate for the Treatment of Otitis Media,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1992, 121(3):459-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/44/27333/abstract-text/1517926/pubmed\" id=\"1517926\" target=\"_blank\">",
"        1517926",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schatz BS, Karavokiros KT, Taeubel MA, et al, &ldquo;Comparison of Cefprozil, Cefpodoxime Proxetil, Loracarbef, Cefixime, and Ceftibuten,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1996, 30(3):258-68.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/44/27333/abstract-text/8833562/pubmed\" id=\"8833562\" target=\"_blank\">",
"        8833562",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9224 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-8E53C3882F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_44_27333=[""].join("\n");
var outline_f26_44_27333=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147808\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147776\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147795\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147777\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147778\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147779\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147748\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147732\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F802618\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147751\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14470554\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147815\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147806\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147754\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147736\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298993\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147741\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147767\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147744\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5951646\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147783\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147757\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147758\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147756\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147746\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147759\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147735\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147753\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9224\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9224|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?11/6/11364?source=related_link\">",
"      Cefpodoxime: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/18/25892?source=related_link\">",
"      Cefpodoxime: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_44_27334="Temazepam: Drug information";
var content_f26_44_27334=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Temazepam: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?2/58/2981?source=see_link\">",
"    see \"Temazepam: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F225182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Restoril&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F225183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Temazepam&reg;;",
"     </li>",
"     <li>",
"      CO Temazepam;",
"     </li>",
"     <li>",
"      Dom-Temazepam;",
"     </li>",
"     <li>",
"      Gen-Temazepam;",
"     </li>",
"     <li>",
"      Novo-Temazepam;",
"     </li>",
"     <li>",
"      Nu-Temazepam;",
"     </li>",
"     <li>",
"      PHL-Temazepam;",
"     </li>",
"     <li>",
"      PMS-Temazepam;",
"     </li>",
"     <li>",
"      ratio-Temazepam;",
"     </li>",
"     <li>",
"      Restoril&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F225217\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Benzodiazepine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F225186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Insomnia:",
"     </b>",
"     Oral: Usual dose: 15-30 mg at bedtime; some patients may respond to 7.5 mg in transient insomnia",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F225187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Initial: 7.5  mg in elderly or debilitated patients at bedtime",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F225160\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 7.5 mg, 15 mg, 22.5 mg, 30 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Restoril&trade;: 7.5 mg, 15 mg, 22.5 mg, 30 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F225145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F225219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-IV",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM233806.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM233806.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F225164\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Short-term treatment of insomnia",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F225213\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of anxiety",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F225226\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Temazepam may be confused with flurazepam, LORazepam, tamoxifen",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Restoril&trade; may be confused with Resotran&trade;, RisperDAL&reg;, Vistaril&reg;, Zestril&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - high; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F225215\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Anxiety, confusion, dizziness, drowsiness, euphoria, fatigue, hangover, headache, lethargy, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Libido decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Dysarthria, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Amnesia, anaphylaxis, angioedema, ataxia, blood dyscrasias, complex sleep-related behavior (sleep-driving, cooking or eating food, making phone calls), drug dependence, paradoxical reactions, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F225167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to temazepam or any component of the formulation (cross-sensitivity with other benzodiazepines may exist); narrow-angle glaucoma (not in product labeling, however, benzodiazepines are contraindicated); pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F225149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anterograde amnesia: Benzodiazepines have been associated with anterograde amnesia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Postmarketing studies have indicated that the use of hypnotic/sedative agents for sleep has been associated with hypersensitivity reactions including anaphylaxis as well as angioedema.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Paradoxical reactions: Paradoxical reactions, including hyperactive or aggressive behavior, have been reported with benzodiazepines, particularly in adolescent/pediatric or psychiatric patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sleep-related activities: An increased risk for hazardous sleep-related activities such as sleep-driving; cooking and eating food, and making phone calls while asleep have also been noted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Depression: Use caution in patients with depression, particularly if suicidal risk may be present.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug abuse: Use with caution in patients with a history of drug abuse or acute alcoholism; potential for drug dependency exists. Tolerance, psychological and physical dependence may occur with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Impaired gag reflex: Use with caution in patients with an impaired gag reflex.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with respiratory disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depressants/psychoactive medications: Use with caution in patients receiving other CNS depressants or psychoactive medication; effects with other sedative drugs or ethanol may be potentiated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Debilitated patients: Use with caution in debilitated patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: In older adults, benzodiazepines increase the risk of impaired cognition, delirium, falls, fractures, and motor vehicle accidents. Due to increased sensitivity in this age group, avoid use for treatment of insomnia, agitation, or delirium. (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fall risk: Use with extreme caution in patients who are at risk of falls; benzodiazepines have been associated with falls and traumatic injury.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Does not have analgesic, antidepressant, or antipsychotic properties.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypnotic: Appropriate use: Should be used only after evaluation of potential causes of sleep disturbance. Failure of sleep disturbance to resolve after 7-10 days may indicate psychiatric or medical illness. A worsening of insomnia or the emergence of new abnormalities of thought or behavior may represent unrecognized psychiatric or medical illness and requires immediate and careful evaluation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal: Rebound or withdrawal symptoms may occur following abrupt discontinuation or large decreases in dose. Use caution when reducing dose or withdrawing therapy; decrease slowly and monitor for withdrawal symptoms. Flumazenil may cause withdrawal in patients receiving long-term benzodiazepine therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F225211\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2B6 (minor), CYP2C19 (minor), CYP2C9 (minor), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F225154\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Benzodiazepines may enhance the adverse/toxic effect of CloZAPine.  Management: Consider decreasing the dose of (or possibly discontinuing) benzodiazepines prior to initiating clozapine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Benzodiazepines may increase the serum concentration of Fosphenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OLANZapine: May enhance the adverse/toxic effect of Benzodiazepines. Management: Avoid concomitant use of parenteral benzodiazepines and IM olanzapine due to risks of additive adverse events (e.g., cardiorespiratory depression). Olanzapine prescribing information provides no specific recommendations regarding oral administration.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Benzodiazepines may increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: Benzodiazepines may enhance the CNS depressant effect of Sodium Oxybate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: May diminish the therapeutic effect of Benzodiazepines.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the therapeutic effect of Antianxiety Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F225178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Serum levels may be increased by grapefruit juice.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease temazepam levels. Avoid valerian, St John's wort, kava kava, gotu kola (may increase CNS depression).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F225155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F11229464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies. Although information specific to the use of temazepam has not been located, all benzodiazepines are assumed to cross the placenta. Teratogenic effects have been observed with some benzodiazepines; however, additional studies are needed. The incidence of premature birth and low birth weights may be increased following maternal use of benzodiazepines; hypoglycemia and respiratory problems in the neonate may occur following exposure late in pregnancy. Neonatal withdrawal symptoms may occur within days to weeks after birth and &ldquo;floppy infant syndrome&rdquo; (which also includes withdrawal symptoms) have been reported with some benzodiazepines. Use during pregnancy is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F225189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution (AAP rates &ldquo;of concern&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F11229465\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Information is available from a study conducted in 10 nursing women, &lt;2 weeks postpartum. All women were given temazepam 10-20 mg at bedtime for &ge;2 nights. Samples were obtained 10-21 hours after a dose. Temazepam was not found in the milk of nine mothers (maternal serum concentrations 8-59 mcg/L). Temazepam was detected in the milk of one patient whose serum concentration was 234 mcg/mL at ~14 hours after the dose; milk concentrations were 28 mcg/L (pre-feed) and 26 mcg/L (post-feed). Oxazepam concentrations were 9 mcg/mL in the maternal serum and below the limit of detection in breast milk. Adverse events were not noted in any nursing infants. Drowsiness, lethargy, or weight loss in nursing infants have been observed in case reports following maternal use of some benzodiazepines.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F225170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Restoril Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5 mg (30): $407.77",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg (100): $1359.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     22.5 mg (30): $407.77",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (100): $1359.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Temazepam Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5 mg (100): $994.03",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg (100): $73.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     22.5 mg (30): $298.21",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (100): $88.45",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F225157\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Respiratory and cardiovascular status",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F225161\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Therapeutic: 26 ng/mL after 24 hours",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F225171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Dasuen (ES);",
"     </li>",
"     <li>",
"      Euhypnos (BE, IE, LU, NZ);",
"     </li>",
"     <li>",
"      Euipnos (IT);",
"     </li>",
"     <li>",
"      Levanxol (AT, BE, LU);",
"     </li>",
"     <li>",
"      Mabertin (AR);",
"     </li>",
"     <li>",
"      Normison (AU, BE, CH, FI, FR, GB, IE, IT, LU, NL, NZ, PT);",
"     </li>",
"     <li>",
"      Nortem (IE);",
"     </li>",
"     <li>",
"      Planum (DE);",
"     </li>",
"     <li>",
"      Restoril (PK);",
"     </li>",
"     <li>",
"      Signopam (HU, PL);",
"     </li>",
"     <li>",
"      Signopharm (HU);",
"     </li>",
"     <li>",
"      Temador (BE);",
"     </li>",
"     <li>",
"      Temaze (AU);",
"     </li>",
"     <li>",
"      Temazepam &rdquo;NM&rdquo; (DK);",
"     </li>",
"     <li>",
"      Tenox (FI, IE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F225148\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds to stereospecific benzodiazepine receptors on the postsynaptic GABA neuron at several sites within the central nervous system, including the limbic system, reticular formation. Enhancement of the inhibitory effect of GABA on neuronal excitability results by increased neuronal membrane permeability to chloride ions. This shift in chloride ions results in hyperpolarization (a less excitable state) and stabilization.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F225166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 1.4 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 96%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 9.5-12.4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (80% to 90% as inactive metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/44/27334/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/44/27334/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bergman U, Rosa FW, Baum C, et al, \"Effects of Exposure to Benzodiazepine During Fetal Life,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 1992, 340(8821):694-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/44/27334/abstract-text/1355799/pubmed\" id=\"1355799\" target=\"_blank\">",
"        1355799",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Divoll M, Greenblatt DJ, Harmatz JS, et al, &ldquo;Effect of Age and Gender on Disposition of Temazepam,&rdquo;",
"      <i>",
"       J Pharm Sci",
"      </i>",
"      , 1981, 70(10):1104-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/44/27334/abstract-text/6117653/pubmed\" id=\"6117653\" target=\"_blank\">",
"        6117653",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grahame-Smith DG, &ldquo;Misuse of Temazepam,&rdquo;",
"      <i>",
"       BMJ",
"      </i>",
"      , 1991, 302(6786):1210.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/44/27334/abstract-text/2043835/pubmed\" id=\"2043835\" target=\"_blank\">",
"        2043835",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ho PC, Triggs EJ, Heazlewood V, et al, &ldquo;Determination of Nitrazepam and Temazepam in Plasma by High Performance Liquid Chromatography,&rdquo;",
"      <i>",
"       Ther Drug Monit",
"      </i>",
"      , 1983, 5(3):303-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/44/27334/abstract-text/6138889/pubmed\" id=\"6138889\" target=\"_blank\">",
"        6138889",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Iqbal MM, Sobhan T, Ryals T, et al, \"Effects of Commonly Used Benzodiazepines on the Fetus, the Neonate, and the Nursing Infant,\"",
"      <i>",
"       Psychiatr Serv",
"      </i>",
"      , 2002, 53(1):39-49.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/44/27334/abstract-text/11773648/pubmed\" id=\"11773648\" target=\"_blank\">",
"        11773648",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Klotz U and Kanto J, &ldquo;Pharmacokinetics and Clinical Use of Flumazenil (Ro 15-1788),&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1988, 14(1):1-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/44/27334/abstract-text/3127102/pubmed\" id=\"3127102\" target=\"_blank\">",
"        3127102",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lebedevs TH, Wojnar-Horton RE, Yapp P, et al, \"Excretion of Temazepam in Breast Milk,\"",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 1992, 33(2):204-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/44/27334/abstract-text/1550703/pubmed\" id=\"1550703\" target=\"_blank\">",
"        1550703",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2003, 123(3):897-922.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/44/27334/abstract-text/12628894/pubmed\" id=\"12628894\" target=\"_blank\">",
"        12628894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Scharf MB, Berkowitz DV, and Brannen DE, &ldquo;Effectiveness of Low-Dose Temazepam on Sleep Patterns in Geriatric Insomniac Subjects,&rdquo;",
"      <i>",
"       Consult Pharm",
"      </i>",
"      , 1993, 8(12):1367-73.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schutte-Rodin S, Broch L, Buysse D, et al, &ldquo;Clinical Guideline for the Evaluation and Management of Chronic Insomnia in Adults,&rdquo;",
"      <i>",
"       J Clin Sleep Med",
"      </i>",
"      , 2008, 4(5):487-504.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/44/27334/abstract-text/18853708/pubmed\" id=\"18853708\" target=\"_blank\">",
"        18853708",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wikner BN, Stiller CO, Bergman U, et al, \"Use of Benzodiazepines and Benzodiazepine Receptor Agonists During Pregnancy: Neonatal Outcome and Congenital Malformations,\"",
"      <i>",
"       Pharmacoepidemiol Drug Saf",
"      </i>",
"      , 2007, 16(11):1203-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/44/27334/abstract-text/17894421/pubmed\" id=\"17894421\" target=\"_blank\">",
"        17894421",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9973 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-221.179.173.170-9A4DD99832-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_44_27334=[""].join("\n");
var outline_f26_44_27334=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225182\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225183\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225217\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225186\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225187\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225160\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225145\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225219\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874997\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225164\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225213\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225226\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225215\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225167\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225149\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225211\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225154\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225178\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225155\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11229464\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225189\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11229465\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225170\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225157\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225161\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225171\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225148\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225166\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9973\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9973|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?2/58/2981?source=related_link\">",
"      Temazepam: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_44_27335="Surgical procedures for breast cancer — Mastectomy and breast conserving therapy";
var content_f26_44_27335=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"topicTitle\">",
"   Patient information: Surgical procedures for breast cancer &mdash; Mastectomy and breast conserving therapy (Beyond the Basics)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/44/27335/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/44/27335/contributors\">",
"     Daniel F Hayes, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/44/27335/contributors\">",
"     Michael S Sabel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/44/27335/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/44/27335/contributors\">",
"     Anees B Chagpar, MD, MSc, MA, MPH, FACS, FRCS(C)",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/44/27335/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/44/27335/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/44/27335/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     BREAST CANCER OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast cancer is the most common female cancer in the United States. Finding and treating breast cancer in the early stages allows many women to be cured.",
"   </p>",
"   <p>",
"    This article will focus on the surgical treatment of breast cancer. An introduction to breast cancer and an overview of treatment for breast cancer is also available. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?11/56/12167?source=see_link\">",
"     \"Patient information: Breast cancer guide to diagnosis and treatment (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BREAST CANCER STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to removing the cancer from the breast and lymph nodes, surgery also provides important information about the \"stage\" of the cancer. The stage of the breast cancer (TNM) is based upon the size of the tumor in the breast (T), status of lymph nodes (N), and metastatic spread to distant sites (M).",
"   </p>",
"   <p>",
"    Staging is discussed in detail in a separate article. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?11/56/12167?source=see_link\">",
"     \"Patient information: Breast cancer guide to diagnosis and treatment (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     FACTORS AFFECTING SURGICAL TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several factors must be considered when choosing the best surgical treatment for your breast cancer. You should discuss these factors with your physician as you decide which treatment is best for you.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Microscopic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The surgeon must determine if a breast cancer is invasive or noninvasive (in situ). (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?11/56/12167?source=see_link&amp;anchor=H10#H10\">",
"     \"Patient information: Breast cancer guide to diagnosis and treatment (Beyond the Basics)\", section on 'Types of breast cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Invasive breast cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Invasive breast cancers usually require surgical treatment (mastectomy or breast conserving therapy) as well as treatment after surgery (called adjuvant treatment). Adjuvant treatment can include radiation as well as systemic treatment such as chemotherapy or endocrine therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Noninvasive (in situ) breast cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Noninvasive or in situ breast cancer is divided into two types: lobular carcinoma in situ (LCIS) and ductal carcinoma in situ (DCIS).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      LCIS &mdash; Women with LCIS have an increased risk of developing breast cancer in the future. However, LCIS does not require treatment. Management of LCIS is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/14/44265?source=see_link\">",
"       \"Atypia and lobular carcinoma in situ: High risk lesions of the breast\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      DCIS &mdash; Women with DCIS require surgical treatment (mastectomy or breast conserving therapy) as well as treatment after surgery (called adjuvant treatment). Adjuvant treatment can include radiation as well as systemic treatment such as endocrine therapy. Chemotherapy is usually not necessary. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/43/37561?source=see_link\">",
"       \"Ductal carcinoma in situ: Treatment and prognosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/41/14998?source=see_link\">",
"       \"Microinvasive breast carcinoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Size of the breast tumor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Larger tumors are more likely to recur and usually require more aggressive treatment. Large tumors (5 cm or about the size of an egg) may require chemotherapy before surgery, which is called neoadjuvant chemotherapy. This is given in order to shrink the tumor and allow for lumpectomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/40/35466?source=see_link\">",
"     \"Neoadjuvant therapy for breast cancer: Rationale, pretreatment evaluation, and therapeutic options\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Tumors that invade the skin and inflammatory breast cancers also require chemotherapy and mastectomy is usually recommended for these more advanced cancers. This is discussed in a separate article. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?5/47/5875?source=see_link\">",
"     \"Patient information: Locally advanced and inflammatory breast cancer (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Spread to the lymph nodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymph nodes (or glands) are usually the first place for breast cancer to spread. If a breast cancer has spread to lymph nodes, it is called",
"    <strong>",
"     node-positive",
"    </strong>",
"    ; a cancer that has not spread to the lymph nodes is called",
"    <strong>",
"     node-negative",
"    </strong>",
"    . If a breast cancer has spread to the lymph nodes, it is twice as likely to have also spread elsewhere, and therefore, to recur.",
"   </p>",
"   <p>",
"    However, even when cancer has spread to the lymph nodes, there is still a chance it has not spread anywhere else in the body. The goal of surgery is to remove cancer from both the breast and the lymph nodes. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Management of axillary lymph nodes'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SURGICAL TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical removal of the tumor is usually the first step in treating early stage breast cancer. If the breast tumor is large or more advanced, treatment with chemotherapy,",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?43/23/44404?source=see_link\">",
"     trastuzumab",
"    </a>",
"    , or sometimes anti-estrogen therapy may be recommended before surgery. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?5/47/5875?source=see_link&amp;anchor=H14#H14\">",
"     \"Patient information: Locally advanced and inflammatory breast cancer (Beyond the Basics)\", section on 'Treatment of locally advanced breast cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are two options for breast surgery:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mastectomy involves removing the entire breast. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Mastectomy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Breast conserving surgery removes just the cancerous area and a small amount of surrounding normal tissue (also called lumpectomy). Breast conserving surgery plus radiation therapy is referred to as breast conserving therapy, or BCT. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Breast conserving therapy (BCT)'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In centers that specialize in breast cancer treatment, approximately 75 percent of women with early stage breast cancer are candidates for BCT. In 25 to 50 percent of women, there are medical, cosmetic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    social and emotional reasons for having a mastectomy rather than BCT. Survival outcomes are the same whether BCT or mastectomy is performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MASTECTOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mastectomy may be necessary because of the location of your tumor, the size or shape of your breast, findings on your imaging examination (mammogram or MRI), whether radiation may be used, or it may be your preference. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/18/12586?source=see_link\">",
"     \"Mastectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Simple mastectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A total or simple mastectomy involves removing the entire breast without removing the axillary lymph nodes. A technique called sentinel lymph node biopsy is performed to be sure that the cancer has not spread to the lymph nodes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Skin-sparing mastectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a skin-sparing mastectomy, the nipple and areola are usually removed but the rest of the skin over the breast is preserved. This is done in conjunction with immediate reconstruction with a plastic surgeon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34879249\">",
"    <span class=\"h2\">",
"     Nipple sparing mastectomy and areola-sparing mastectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because there is breast tissue extending to the nipple areolar complex (NAC), standard mastectomies (both simple and skin-sparing) usually involve removing the NAC. However, for certain subsets of patients, it may be safe to preserve either the entire NAC (the nipple sparing mastectomy, NSM) or remove the nipple with the breast tissue but preserve the areola (areola-sparing mastectomy, ASM). As with the skin-sparing mastectomy, these are done in conjunction with immediate reconstruction with a plastic surgeon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10913023\">",
"    <span class=\"h2\">",
"     Modified radical mastectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;During a modified radical mastectomy (MRM), the breast tissue and the lymph nodes in the armpit (the axillary lymph nodes) are removed. An axillary node dissection is necessary only if the cancer has spread to the lymph nodes. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Management of axillary lymph nodes'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10912951\">",
"    <span class=\"h2\">",
"     Breast reconstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reconstruction of the breast is an important option for women who undergo mastectomy. You may choose to have breast reconstruction immediately after the mastectomy or at a later time. The nipples may also be reconstructed to allow the breast to appear more natural. There are several options for reconstruction, and all women planning to undergo mastectomy should see a plastic or reconstructive surgeon to discuss these options before having breast surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/29/39386?source=see_link\">",
"     \"Breast reconstruction in women with breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Complications of mastectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mastectomy is generally a safe surgery, although complications can occur, including bleeding, collection of fluid, wound infection, and arm problems. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?15/32/15876?source=see_link\">",
"     \"Patient information: Lymphedema after breast cancer surgery (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Radiation therapy after mastectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation therapy is sometimes recommended after a mastectomy to decrease the chance of a recurrence, especially in women who have large tumors (5 cm in size or larger), have tumors close to the chest wall, or who have four or more positive lymph nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27335/abstract/1\">",
"     1",
"    </a>",
"    ]. The benefit of radiation after mastectomy for women with smaller tumors or fewer involved lymph nodes is controversial.",
"   </p>",
"   <p>",
"    More information about radiation therapy is available below. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Radiation therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     BREAST CONSERVING THERAPY (BCT)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast conserving therapy refers to surgical removal of the tumor and a small portion of normal surrounding breast tissue. BCT is almost always followed by radiation therapy to the remaining breast tissue. Breast conserving surgery is also called a partial mastectomy, and less accurately, a lumpectomy. A partial mastectomy is the most commonly performed BCT procedure in the United States and Canada.",
"   </p>",
"   <p>",
"    A quadrantectomy, which is more often used outside of North America, refers to removal of the tumor and about one-fourth of the breast tissue on that side. The remainder of this article will use the word lumpectomy, although the information also applies to women who have had a quadrantectomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/42/31402?source=see_link\">",
"     \"Breast conserving therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Radiation therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Invasive breast cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation therapy (RT) refers to the exposure of a tumor to high-energy x-rays in order to slow or stop its growth. Exposure to x-rays damages cells. Unlike normal cells, cancer cells cannot repair the damage caused by exposure to x-rays over several days. This prevents the cancer cells from growing further and causes them to eventually die.",
"   </p>",
"   <p>",
"    RT for breast cancer is mostly given as external beam RT, meaning that the radiation beam is generated by a machine that is outside the patient. Exposure to the beam typically takes only a few seconds (similar to having an x-ray). In general, RT is given daily, five days per week, for approximately five to six weeks. Some patients may be candidates for an accelerated course of RT, which is only given to the part of the breast where the cancer was removed. This is called &ldquo;accelerated partial breast irradiation&rdquo;.",
"   </p>",
"   <p>",
"    Radiation is generally recommended for most women who have had breast conserving surgery for invasive breast cancer, even if the tumor is very small. The goal of this treatment is to kill any remaining cancer cells. Some women, particularly those with many other medical conditions, may be safely treated without radiation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     In situ breast cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most women with ductal carcinoma in situ (DCIS) will be advised to have radiation therapy after breast conserving surgery. This will depend on the size and grade of the DCIS, your age, and whether the DCIS is hormone receptor positive. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/33/6680?source=see_link\">",
"     \"Breast ductal carcinoma in situ: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/43/37561?source=see_link\">",
"     \"Ductal carcinoma in situ: Treatment and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/41/14998?source=see_link\">",
"     \"Microinvasive breast carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Cosmetic outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;With modern surgical techniques, cosmetic results are good to excellent in most women after breast conserving therapy (ie, the treated and untreated breast are almost identical or there are only slight differences). The effects of BCT on the appearance of the breast take about three years to stabilize. Factors such as weight gain and the normal age-related sagging of breast tissue also affect the shape and size of the breasts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Complications following BCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following breast conserving surgery or radiation, complications can sometimes occur, including bleeding, pain, infection or collection of fluid.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     MASTECTOMY VERSUS BREAST CONSERVING THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies show that women with localized breast cancer are",
"    <strong>",
"     equally likely",
"    </strong>",
"    to survive their cancer whether they are treated with BCT or a mastectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27335/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Factors to consider",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although cancer outcomes are similar, there are several factors that you should consider when trying to decide between BCT and mastectomy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Tumor size",
"      </strong>",
"      &mdash; Some women who have a large tumor and small breasts are advised to undergo mastectomy rather than BCT. However, chemotherapy may be given before surgery to shrink the tumor; this may allow the woman to have breast conserving surgery, if she desires it.",
"     </li>",
"     <li>",
"      <strong>",
"       Extensive DCIS",
"      </strong>",
"      ��� Extensive ductal carcinoma in situ (DCIS), a very early cancer, does not respond well to chemotherapy and therefore may necessitate a mastectomy in order to make sure that all the disease is removed.",
"     </li>",
"     <li>",
"      <strong>",
"       Tumor margins",
"      </strong>",
"      ��� After lumpectomy, it is important to have a margin of normal breast tissue around the tumor. If cancer cells are found at or near the edges of the tissue removed, additional surgery may be necessary. If a large amount of tissue has been removed and the margins are still involved, mastectomy may be recommended.",
"     </li>",
"     <li>",
"      <strong>",
"       Tumor location ���",
"      </strong>",
"      Tumors that are in the center of the breast or involve the nipple or the skin, may be treated with a mastectomy or breast conserving surgery, depending upon the expected cosmetic results.",
"     </li>",
"     <li>",
"      <strong>",
"       Need for radiation",
"      </strong>",
"      ��� BCT involves both lumpectomy and radiation. In addition, while radiation does allow for preservation of the breast, there are both immediate and long-term side effects. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39657?source=see_link\">",
"       \"Techniques of breast and chest wall irradiation for early stage breast cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Risk reduction",
"      </strong>",
"      ��� Some patients will opt to have a mastectomy (often on both sides) to reduce the risk of future breast cancers. &nbsp;This is particularly the case in women who carry a breast cancer gene mutation or those with significant risk factors (eg, lobular carcinoma in situ or a significant family history)",
"     </li>",
"     <li>",
"      <strong>",
"       Individual needs and preferences",
"      </strong>",
"      &mdash; You should discuss your preferences and concerns about preserving your breast with your doctor.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Reasons to avoid BCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain factors",
"    <strong>",
"     clearly",
"    </strong>",
"    favor mastectomy over BCT. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Multiple tumors ���",
"      </strong>",
"      Having two or more separate tumors in different areas of the breast.",
"      <strong>",
"      </strong>",
"      Some patients have more than one cancer in the breast and it may not be possible to remove all of the tumors and still save the breast.",
"     </li>",
"     <li>",
"      <strong>",
"       Extensive tumor",
"      </strong>",
"      ��� If tumor is spread throughout the breast tissue, it will not be possible to remove the entire tumor without a mastectomy.",
"     </li>",
"     <li>",
"      <strong>",
"       Contraindication for radiation ���",
"      </strong>",
"      Some women are not candidates for radiation, such as women who are pregnant, have already had radiation to the area, or with conditions that make radiation dangerous, such as lupus skin disease.",
"     </li>",
"     <li>",
"      <strong>",
"       Risk of a second breast cancer ���",
"      </strong>",
"      Some women may be candidates for BCT but may be at a high risk of developing another breast cancer. These include very young women, women with a known breast cancer gene mutation or women with a very strong family history of breast cancer. These women may consider bilateral mastectomy to not only treat the known cancer, but prevent a second cancer in the future.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Factors that do not affect your decision",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several factors",
"    <strong>",
"     do not",
"    </strong>",
"    play a role in the choice between BCT and mastectomy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The spread of cancer cells to lymph nodes in the armpit",
"     </li>",
"     <li>",
"      A family history of breast cancer",
"     </li>",
"     <li>",
"      A high likelihood that cancer will metastasize or spread to other locations in your body",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF AXILLARY LYMPH NODES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most women with invasive cancer will have an operation to check for cancer cells in the axillary lymph nodes. Women with ductal carcinoma in situ (DCIS) have a very small chance of having cancer cells spreading to the axillary lymph nodes. In general, SLN biopsy is not recommended for women with DCIS unless a mastectomy is being performed. In that case, SLN is done since, if invasive cancer is found in the mastectomy specimen, the surgeon cannot go back and do a SLN procedure after a mastectomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34879371\">",
"    <span class=\"h2\">",
"     Axillary lymph node dissection",
"    </span>",
"    &nbsp;&mdash;&nbsp;This procedure involves removing most of the lymph nodes in the axilla (armpit) to examine them for cancer cells and to help prevent the spread of the cancer to distant sites (such as the lung). This operation was commonly performed for women with invasive breast cancer in the past and is associated with complications such as pain and arm swelling (lymphedema). An axillary lymph node dissection is now usually performed only when the sentinel node or another lymph node in the axilla contain cancer cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Sentinel lymph node biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The idea of a sentinel lymph node (SLN) is based on the fact that breast tumor cells first involve one or a few lymph nodes before involving lymph nodes in other areas or spreading (metastasizing) to distant organs. To identify this sentinel node, the surgeon injects blue dye, a radioactive material, or a combination of both into the breast. The dye enters the lymphatic channels and flows to the sentinel lymph node or nodes, which helps the surgeon identify and remove the appropriate lymph nodes.",
"   </p>",
"   <p>",
"    The sentinel node or nodes are removed and examined under the microscope. If these nodes do not contain any cancer cells, there is only a small chance that other axillary nodes will be positive; removal of additional axillary lymph nodes is not necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27335/abstract/1\">",
"     1",
"    </a>",
"    ]. Most patients do not have cancer in their sentinel lymph nodes and will not need additional surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/47/36602?source=see_link\">",
"     \"Sentinel lymph node dissection for breast cancer: Indications and outcomes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     TREATMENT AFTER SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment after surgery, called adjuvant treatment, is often recommended for women with invasive breast cancer. Adjuvant treatment is discussed in a separate article. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?25/52/26437?source=see_link\">",
"     \"Patient information: Early stage breast cancer treatment in postmenopausal women (Beyond the Basics)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?39/2/39970?source=see_link\">",
"     \"Patient information: Early stage breast cancer treatment in premenopausal women (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SURVEILLANCE AFTER INITIAL TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;After being treated for breast cancer, there is a risk that breast cancer will recur. Breast cancer survivors are advised to see their oncologist every three to six months for the first three years after treatment, every 6 to 12 months for the next two years, and then annually.",
"   </p>",
"   <p>",
"    Women who have undergone BCT are advised to continue breast self-exams and mammography. Screening mammography after mastectomy and breast reconstruction is usually not recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/12/5322?source=see_link\">",
"     \"Approach to the long-term survivor of breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A summary of the American Society of Clinical Oncology's recommendations for surveillance after breast cancer treatment is provided in the table (",
"    <a class=\"graphic graphic_table graphicRef77225 \" href=\"UTD.htm?9/63/10236\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     WHERE TO GET MORE INFORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"   </p>",
"   <p>",
"    This article will be updated as needed on our web site (",
"    <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"     www.uptodate.com/patients",
"    </a>",
"    ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32164801\">",
"    <span class=\"h2\">",
"     Patient level information",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32164808\">",
"    <span class=\"h3\">",
"     The Basics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"   </p>",
"   <p>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?2/19/2357?source=see_link\">",
"     Patient information: Breast cancer (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?10/62/11236?source=see_link\">",
"     Patient information: Breast reconstruction after mastectomy (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?8/8/8321?source=see_link\">",
"     Patient information: Choosing treatment for early-stage breast cancer (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?3/26/3492?source=see_link\">",
"     Patient information: Ductal carcinoma in situ (DCIS) (The Basics)",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32164930\">",
"    <span class=\"h3\">",
"     Beyond the Basics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    <br/>",
"   </p>",
"   <p>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?11/56/12167?source=see_link\">",
"     Patient information: Breast cancer guide to diagnosis and treatment (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?15/32/15876?source=see_link\">",
"     Patient information: Lymphedema after breast cancer surgery (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?5/47/5875?source=see_link\">",
"     Patient information: Locally advanced and inflammatory breast cancer (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?25/52/26437?source=see_link\">",
"     Patient information: Early stage breast cancer treatment in postmenopausal women (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?39/2/39970?source=see_link\">",
"     Patient information: Early stage breast cancer treatment in premenopausal women (Beyond the Basics)",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32164945\">",
"    <span class=\"h2\">",
"     Professional level information",
"    </span>",
"    &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Professional Level Information:",
"    </span>",
"   </p>",
"   <p>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/46/19177?source=see_link\">",
"     Overview of the treatment of newly diagnosed, non-metastatic breast cancer",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/14/44265?source=see_link\">",
"     Atypia and lobular carcinoma in situ: High risk lesions of the breast",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/42/31402?source=see_link\">",
"     Breast conserving therapy",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/33/6680?source=see_link\">",
"     Breast ductal carcinoma in situ: Epidemiology, clinical manifestations, and diagnosis",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/43/37561?source=see_link\">",
"     Ductal carcinoma in situ: Treatment and prognosis",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/29/39386?source=see_link\">",
"     Breast reconstruction in women with breast cancer",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19194?source=see_link\">",
"     Hormone receptors in breast cancer: Clinical utility and guideline recommendations to improve test accuracy",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/18/12586?source=see_link\">",
"     Mastectomy",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/41/14998?source=see_link\">",
"     Microinvasive breast carcinoma",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/47/36602?source=see_link\">",
"     Sentinel lymph node dissection for breast cancer: Indications and outcomes",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39657?source=see_link\">",
"     Techniques of breast and chest wall irradiation for early stage breast cancer",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/12/5322?source=see_link\">",
"     Approach to the long-term survivor of breast cancer",
"    </a>",
"    <br/>",
"    <br/>",
"    The following organizations also provide reliable health information.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      National Cancer Institute",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; 1-800-4-CANCER",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; (",
"    <a class=\"external\" href=\"file://www.nci.nih.gov/\">",
"     www.nci.nih.gov",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      American Society of Clinical Oncology",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;(",
"    <a class=\"external\" href=\"file://www.cancer.net/portal/site/patient\">",
"     www.cancer.net/portal/site/patient",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      National Comprehensive Cancer Network",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;(",
"    <a class=\"external\" href=\"file://www.nccn.org/\">",
"     www.nccn.org",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      American Cancer Society",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; 1-800-ACS-2345",
"    <br/>",
"    &nbsp; &nbsp; &nbsp;(",
"    <a class=\"external\" href=\"file://www.cancer.org/\">",
"     www.cancer.org",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      National Library of Medicine",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;(",
"    <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"     www.nlm.nih.gov/medlineplus/healthtopics.html",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Susan G. Komen Breast Cancer Foundation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; (",
"    <a class=\"external\" href=\"file://www.komen.org/\">",
"     www.komen.org",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Patient support",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of online forums where patients can find information and support from other people with similar conditions.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"external\" href=\"file://about.com/\">",
"       About.com",
"      </a>",
"      Breast Cancer Forum",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;(",
"    <a class=\"external\" href=\"file://breastcancer.about.com/forum\">",
"     file://breastcancer.about.com/forum",
"    </a>",
"    )",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27335/abstract/1\">",
"      Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 366:2087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27335/abstract/2\">",
"      Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials. Early Breast Cancer Trialists' Collaborative Group. N Engl J Med 1995; 333:1444.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 881 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-41.222.196.37-062E1C4994-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_44_27335=[""].join("\n");
var outline_f26_44_27335=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      BREAST CANCER OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BREAST CANCER STAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      FACTORS AFFECTING SURGICAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Microscopic findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Invasive breast cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Noninvasive (in situ) breast cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Size of the breast tumor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Spread to the lymph nodes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SURGICAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MASTECTOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Simple mastectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Skin-sparing mastectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34879249\">",
"      Nipple sparing mastectomy and areola-sparing mastectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10913023\">",
"      Modified radical mastectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10912951\">",
"      Breast reconstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Complications of mastectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Radiation therapy after mastectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      BREAST CONSERVING THERAPY (BCT)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Invasive breast cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - In situ breast cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Cosmetic outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Complications following BCT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      MASTECTOMY VERSUS BREAST CONSERVING THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Factors to consider",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Reasons to avoid BCT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Factors that do not affect your decision",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      MANAGEMENT OF AXILLARY LYMPH NODES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34879371\">",
"      Axillary lymph node dissection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Sentinel lymph node biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      TREATMENT AFTER SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SURVEILLANCE AFTER INITIAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      WHERE TO GET MORE INFORMATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32164801\">",
"      Patient level information",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32164808\">",
"      - The Basics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32164930\">",
"      - Beyond the Basics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32164945\">",
"      Professional level information",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Professional Level Information:",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Patient support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/881\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PI/881|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/63/10236\" title=\"table 1\">",
"      Breast ca surveillance PI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/12/5322?source=related_link\">",
"      Approach to the long-term survivor of breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/14/44265?source=related_link\">",
"      Atypia and lobular carcinoma in situ: High risk lesions of the breast",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/42/31402?source=related_link\">",
"      Breast conserving therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/33/6680?source=related_link\">",
"      Breast ductal carcinoma in situ: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/29/39386?source=related_link\">",
"      Breast reconstruction in women with breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/43/37561?source=related_link\">",
"      Ductal carcinoma in situ: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19194?source=related_link\">",
"      Hormone receptors in breast cancer: Clinical utility and guideline recommendations to improve test accuracy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/18/12586?source=related_link\">",
"      Mastectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/41/14998?source=related_link\">",
"      Microinvasive breast carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/40/35466?source=related_link\">",
"      Neoadjuvant therapy for breast cancer: Rationale, pretreatment evaluation, and therapeutic options",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/46/19177?source=related_link\">",
"      Overview of the treatment of newly diagnosed, non-metastatic breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/19/2357?source=related_link\">",
"      Patient information: Breast cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/56/12167?source=related_link\">",
"      Patient information: Breast cancer guide to diagnosis and treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/62/11236?source=related_link\">",
"      Patient information: Breast reconstruction after mastectomy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/8/8321?source=related_link\">",
"      Patient information: Choosing treatment for early-stage breast cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/26/3492?source=related_link\">",
"      Patient information: Ductal carcinoma in situ (DCIS) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/52/26437?source=related_link\">",
"      Patient information: Early stage breast cancer treatment in postmenopausal women (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/2/39970?source=related_link\">",
"      Patient information: Early stage breast cancer treatment in premenopausal women (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/47/5875?source=related_link\">",
"      Patient information: Locally advanced and inflammatory breast cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/32/15876?source=related_link\">",
"      Patient information: Lymphedema after breast cancer surgery (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/47/36602?source=related_link\">",
"      Sentinel lymph node dissection for breast cancer: Indications and outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39657?source=related_link\">",
"      Techniques of breast and chest wall irradiation for early stage breast cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_44_27336="Management of postpartum hemorrhage at cesarean delivery";
var content_f26_44_27336=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of postpartum hemorrhage at cesarean delivery",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/44/27336/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/44/27336/contributors\">",
"     Allan J Jacobs, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/44/27336/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/44/27336/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/44/27336/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/44/27336/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/44/27336/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to treatment of postpartum hemorrhage (PPH) differs somewhat depending on the cause and whether hemorrhage occurs after a vaginal birth or after a cesarean delivery. Furthermore, the approach varies depending on whether the bleeding is discovered during or after the operation.",
"   </p>",
"   <p>",
"    This topic will discuss the approach to the patient with hemorrhage associated with cesarean delivery. As with hemorrhage after vaginal delivery, the key to management is to identify the cause of bleeding and to initiate appropriate intervention. Increasingly, hospitals have adopted policies, protocols and guidelines to deal with massive obstetric hemorrhage. A physician practicing obstetrics should be aware of the existence and content of such protocols.",
"   </p>",
"   <p>",
"    An overview of issues related to diagnosis and management of postpartum hemorrhage and the approach to the patient with PPH after vaginal delivery are reviewed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/38/42600?source=see_link\">",
"       \"Overview of postpartum hemorrhage\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/60/41929?source=see_link\">",
"       \"Management of postpartum hemorrhage at vaginal delivery\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Causes of PPH after cesarean delivery include uterine atony, placenta",
"    <span class=\"nowrap\">",
"     accreta/increta/percreta,",
"    </span>",
"    bleeding from the uterine incision or extensions of this incision, retained placenta, and bleeding from vaginal or cervical tears or uterine rupture. Uterine atony can be isolated or associated with one or more of the other causes of hemorrhage. Cervical and vaginal lacerations typically occur after a long labor with complete or nearly complete dilatation. They can develop spontaneously, during a trial of forceps or vacuum extraction, or during cesarean delivery when the operator attempts to dislodge a fetal head wedged deep in the pelvis. Serious hemorrhage from the uterine incision is generally caused by lateral extension, which can result from excessive traction when creating the incision or from tears resulting from delivery of the fetus through an incision that is too small.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;After delivery of the placenta, the volume and source(s) of bleeding are routinely assessed. As discussed above, excessive bleeding may be related to poor myometrial tone",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    associated with lacerations, incisions, or focal areas of endometrial abnormality.",
"   </p>",
"   <p>",
"    The diagnosis of uterine atony is made if the uterus does not become firm after uterine massage and administration of uterotonic agents. Bleeding from lateral extension of the uterine incision from cesarean is readily ascertained by inspection of the incision. Similarly, inspection of the endometrial cavity will reveal any retained placental fragments. Placenta accreta should be suspected if the placenta does not separate readily, but can be present even if placental delivery appeared to be complete. Placenta accreta usually manifests as hemorrhage from an implantation site in the lower uterine segment. The presence of cervical and lower genital tract lacerations may not be noted until excessive vaginal bleeding postoperatively prompts lower genital tract examination. Ideally, the perineum should be inspected in the operating room to determine if there is active vaginal bleeding and, if bleeding lacerations are present, they should be repaired.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     INITIAL MANAGEMENT",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fluid and blood are administered for resuscitation.",
"     </li>",
"     <li>",
"      Laboratory tests are performed to assess blood loss and coagulopathy and to type and cross for multiple units of packed red blood cells. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/60/41929?source=see_link&amp;anchor=H5#H5\">",
"       \"Management of postpartum hemorrhage at vaginal delivery\", section on 'Laboratory tests'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/60/41929?source=see_link&amp;anchor=H7#H7\">",
"       \"Management of postpartum hemorrhage at vaginal delivery\", section on 'Fluid resuscitation and transfusion'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Fibrinogen level at the time of diagnosis of PPH is predictive of the severity and can be used to guide the aggressiveness of management. A low fibrinogen level (less than 200",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"      is predictive of severe postpartum hemorrhage (ie, need for transfusion of multiple units of blood, need for angiographic embolization or surgical management of hemorrhage, maternal death) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/44/27336/abstract/1\">",
"       1",
"      </a>",
"      ]. However, an obstetrician certainly should not wait for return of laboratory data if clinical circumstances warrant prompt treatment of massive hemorrhage.",
"     </li>",
"     <li>",
"      If atony is present or suspected, fundal massage and uterotonic drugs are used to contract the uterus. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/60/41929?source=see_link&amp;anchor=H6#H6\">",
"       \"Management of postpartum hemorrhage at vaginal delivery\", section on 'Uterotonic drugs'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Incisional bleeding &mdash; Bleeding from a uterine cesarean incision can generally be controlled by suture ligation. The angles of a transverse incision should be clearly visualized to ensure that they, and any retracted vessels, are ligated. This generally requires extracorporealization of the fundus with traction and adequate lateral retraction. It is possible to ligate the ureter on the same side as a lateral extension of a uterine incision; therefore, the ipsilateral ureter should be identified before bleeding is controlled, if possible, and certainly after control of hemorrhage. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Post-laparotomy inspection'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Specific interventions for control of bleeding from placenta accreta are discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/7/8311?source=see_link\">",
"       \"Clinical features and diagnosis of placenta accreta, increta, and percreta\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     INTRAOPERATIVE INTERVENTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of interventions can be useful to control PPH. Clinicians should use their clinical judgment in deciding whether to expend time attempting one or more of these interventions in a patient with severe hemorrhage who is better served by hysterectomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Uterine artery and utero-ovarian artery ligation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bilateral ligation of the uterine vessels (O'Leary stitch) to control PPH has become a first-line procedure for controlling uterine bleeding at laparotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27336/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. It is preferable to internal iliac artery ligation because the uterine arteries are more readily accessible, the procedure is technically easier, and there is less risk to major adjacent vessels and the ureter (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Internal iliac artery ligation'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Uterine artery ligation is primarily indicated when bleeding is due to laceration of the uterine or ovarian artery, but can also temporarily decrease bleeding from other etiologies. Although it will not control bleeding from uterine atony or placenta accreta, it may decrease blood loss while other interventions are being attempted.",
"   </p>",
"   <p>",
"    After identification of the ureter, we pass a large curved needle with a #0 chromic catgut or polyglycolic acid suture through the lateral aspect of the lower uterine segment as close to the cervix as possible, then back through the broad ligament just lateral to the uterine vessels. The suture is tied to compress these vessels. If this does not control bleeding, the vessels of the utero-ovarian arcade are similarly ligated just distal to the cornua by passing a suture ligature through the myometrium just medial to the vessels, then back through the broad ligament just lateral to the vessels, and then tying to compress the vessels (",
"    <a class=\"graphic graphic_figure graphicRef77881 \" href=\"UTD.htm?6/32/6657\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Bilateral ligation of the arteries and veins (uterine and utero-ovarian) is successful in controlling hemorrhage in over 90 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27336/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Uterine necrosis and placental insufficiency in a subsequent pregnancy have not been described as complications [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27336/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. However, there is a single case report of ovarian failure and development of intrauterine synechiae after postpartum ligation of the uterine, utero-ovarian, and ovarian arteries for PPH related to atony [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27336/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Internal iliac artery ligation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bilateral ligation of the internal iliac arteries (hypogastric arteries) has been used to control uterine hemorrhage by reducing pulse pressure of blood flowing to the uterus [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27336/abstract/7\">",
"     7",
"    </a>",
"    ]. The technique is difficult, especially with a large uterus, a small transverse incision, a pelvis full of blood, and a surgeon who rarely operates in the pelvic retroperitoneal space [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27336/abstract/8\">",
"     8",
"    </a>",
"    ]. For these reasons, uterine artery ligation has largely replaced this procedure. The procedure is described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/18/43305?source=see_link\">",
"     \"Management of hemorrhage in gynecologic surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Uterine compression sutures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uterine compression sutures are an effective method for reducing uterine blood loss related to atony. Procedure-related complications, such as uterine necrosis, erosion, and pyometra, have been reported, but are rare [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27336/abstract/9-14\">",
"     9-14",
"    </a>",
"    ]. Uterine synechiae have been reported on postpartum hysteroscopy or hysterosalpingogram, although some of these women may have been curetted as well [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27336/abstract/15\">",
"     15",
"    </a>",
"    ]. Limited follow-up of women who have had a uterine compression suture suggests that there are no adverse effects on future pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27336/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The specific placement of compression sutures is determined by the operator at the time of laparotomy, and their location requires operator judgment. Generally, longitudinal sutures should be easier to place and should be safer than transverse sutures, but this may not always be the case. If uterine atony persists after administration of uterotonic drugs, compression sutures should be placed promptly, as delaying placement by more than an hour increases the likelihood that hysterectomy will be needed [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27336/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The B-Lynch suture is the most common technique for uterine compression; several variations of this technique have been described and no technique has been proven significantly more effective than another [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27336/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     B-Lynch suture",
"    </span>",
"    &nbsp;&mdash;&nbsp;The B-Lynch suture envelops and compresses the uterus, similar to the result achieved with manual uterine compression [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27336/abstract/18\">",
"     18",
"    </a>",
"    ]. In case reports and small series, it has been highly successful in controlling uterine bleeding from atony when other methods have failed [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27336/abstract/18-22\">",
"     18-22",
"    </a>",
"    ]. The technique is relatively simple to learn, appears safe, and preserves future reproductive potential. It should only be used in cases of uterine atony; it will not control hemorrhage from placenta accreta.",
"   </p>",
"   <p>",
"    A large Mayo needle with #1 or #2 chromic catgut is used to enter and exit the uterine cavity laterally in the lower uterine segment (",
"    <a class=\"graphic graphic_figure graphicRef71907 \" href=\"UTD.htm?0/22/356\">",
"     figure 2",
"    </a>",
"    ). A large suture is used to prevent breaking and a rapid absorption is important to prevent a herniation of bowel through a suture loop after the uterus has involuted.",
"   </p>",
"   <p>",
"    The suture is looped over the fundus and reenters the lower uterine cavity through the posterior wall. The suture then crosses to the other side of the lower uterine segment, exits through the posterior wall, and is looped back over the fundus to enter the anterior lateral lower uterine segment opposite and parallel to the initial bites. The free ends are pulled tightly and tied down securely to compress the uterus, assisted by bimanual compression.",
"   </p>",
"   <p>",
"    The technique has been used alone and in combination with balloon tamponade. This combination has been called the \"uterine sandwich\". (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22711?source=see_link\">",
"     \"Intrauterine balloon tamponade for control of postpartum hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Other techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other techniques have been reported in small case series and represent modifications of the B-Lynch suture [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27336/abstract/20,23-30\">",
"     20,23-30",
"    </a>",
"    ]. Hayman described placement of two to four vertical compression sutures from the anterior to posterior uterine wall without hysterotomy (",
"    <a class=\"graphic graphic_figure graphicRef59142 \" href=\"UTD.htm?35/48/36623\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27336/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. A transverse cervicoisthmic suture can also be placed if needed to control bleeding from the lower uterine segment. Pereira described a technique in which a series of transverse and longitudinal sutures of a delayed absorbable multifilament suture are placed around the uterus via a series of bites into the subserosal myometrium, without entering the uterine cavity (",
"    <a class=\"graphic graphic_figure graphicRef64085 \" href=\"UTD.htm?4/44/4800\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27336/abstract/25\">",
"     25",
"    </a>",
"    ]. Two or three rows of these sutures are placed in each direction to completely envelope and compress the uterus. The longitudinal sutures begin and end tied to the transverse suture nearest the cervix. When the transverse sutures are brought through the broad ligament, care should be taken to avoid damaging blood vessels, ureters, and fallopian tubes. The myometrium should be manually compressed prior to tying down the sutures to facilitate maximal compression. The multiple",
"    <span class=\"nowrap\">",
"     squares/rectangles",
"    </span>",
"    technique of Cho is another variation (",
"    <a class=\"graphic graphic_figure graphicRef58733 \" href=\"UTD.htm?27/7/27775\">",
"     figure 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27336/abstract/27,31\">",
"     27,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Balloon tamponade",
"    </span>",
"    &nbsp;&mdash;&nbsp;Devices such as the Bakri tamponade balloon and the BT-Cath have been used successfully to tamponade bleeding from the uterine cavity after vaginal delivery. For each device, the balloon is filled until bleeding is controlled; continued excessive bleeding indicates that tamponade is not effective. The technique has been used alone and in combination with uterine compression sutures (\"uterine sandwich\")",
"   </p>",
"   <p>",
"    Balloon tamponade after cesarean delivery is performed while the surgeon has direct vision of the uterus, but there are few published reports describing outcomes. These data and the use of these devices are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22711?source=see_link\">",
"     \"Intrauterine balloon tamponade for control of postpartum hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Hysterectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hysterectomy is the last resort, but should not be delayed in women who require prompt control of uterine hemorrhage to prevent death. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/43/29367?source=see_link\">",
"     \"Peripartum hysterectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Post-laparotomy inspection",
"    </span>",
"    &nbsp;&mdash;&nbsp;At the completion of the laparotomy, the operative field should be inspected carefully for hemostasis. Microvascular bleeding usually can be controlled using topic hemostatic agents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/18/43305?source=see_link\">",
"     \"Management of hemorrhage in gynecologic surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The bladder should be inspected and the ureters identified. If there is a possibility of bladder laceration, then 200 mL of saline mixed with 5 mL of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/10/15522?source=see_link\">",
"     indigo carmine",
"    </a>",
"    can be infused into the bladder through the Foley catheter. Integrity of the bladder is confirmed by failure of the colored fluid to leak through the serosa.",
"   </p>",
"   <p>",
"    The ureter should generally be identified before abdominal closure either by transillumination through the broad ligament or direct visual identification during retroperitoneal dissection (",
"    <a class=\"graphic graphic_figure graphicRef64999 \" href=\"UTD.htm?15/44/16069\">",
"     figure 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef76698 \" href=\"UTD.htm?13/34/13859\">",
"     figure 7",
"    </a>",
"    ). It courses horizontally along the peritoneum 1 to 5 cm dorsal to the ovarian vessels and can be identified readily as it passes ventral to the bifurcation of the common iliac artery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/27/41400?source=see_link\">",
"     \"Surgical female pelvic anatomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The ureters should be inspected to confirm that they are not damaged. Their integrity can be assessed by injecting two ampules (10 mL) of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/10/15522?source=see_link\">",
"     indigo carmine",
"    </a>",
"    intravenously. A ureter that has been severed will release blue urine into the pelvis in 10 to 15 minutes. If a ureter has been ligated, cystoscopy or direct visualization of the ureters through a cystotomy will demonstrate that urine is only passing through one of the two ureteral orifices. Passage of a ureteral stent can also be employed to localize the site of obstruction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/57/29592?source=see_link\">",
"     \"Diagnostic cystourethroscopy for gynecologic conditions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19762763\">",
"    <span class=\"h2\">",
"     Management of diffuse oozing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical hemostatic agents can be helpful for management of diffuse light bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/18/43305?source=see_link&amp;anchor=H15#H15\">",
"     \"Management of hemorrhage in gynecologic surgery\", section on 'Manage diffuse bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     TEMPORIZING MEASURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Aortic compression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe bleeding may pose a threat of exsanguination within a few minutes. In these cases, the surgeon should palpate the aorta a few centimeters superior to the sacral promontory and compress the aorta just proximal to the bifurcation. This will markedly slow the volume of bleeding and affords a better opportunity for finding and controlling the source of hemorrhage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19762787\">",
"    <span class=\"h2\">",
"     Uterine tourniquet",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tourniquets have been used to control bleeding at myomectomy, and for other types of pelvic hemorrhage, and may be useful as a temporizing measure in PPH [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27336/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/54/10088?source=see_link&amp;anchor=H1388953#H1388953\">",
"     \"Techniques to reduce blood loss during abdominal or laparoscopic myomectomy\", section on 'Tourniquets and clamps'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Intraoperative cell salvage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraoperative blood salvage with a leukocyte filter and autotransfusion is another option, but its use is investigational in the obstetrical setting [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27336/abstract/33-36\">",
"     33-36",
"    </a>",
"    ]. Although there is a theoretical concern that reinfusing amniotic fluid may cause amniotic fluid embolism, this has been documented only once [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27336/abstract/37\">",
"     37",
"    </a>",
"    ]. Salvaged blood also may be contaminated by fetal erythrocytes. This is not a major concern as Rh(D) alloimmunization in an Rh(D) negative mother can be prevented by administration of anti-D immunoglobulin and ABO incompatibility reactions are unlikely to be serious because the volume of fetal blood contamination is small and A and B",
"    <span class=\"nowrap\">",
"     antigens/antibodies",
"    </span>",
"    are not fully developed at birth. In addition, these risks are probably less than or similar to those from allogeneic transfusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Pelvic packing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with continued severe hemorrhage after hysterectomy can enter a lethal downward spiral characterized by hypothermia, coagulopathy, and metabolic acidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27336/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. Criteria proposed for this \"in extremis\" state include pH &lt;7.30, temperature &lt;35 degrees Celsius, combined resuscitation and procedural time &gt;90 minutes, nonmechanical bleeding, and transfusion requirement &gt;10 units packed RBCs [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27336/abstract/40\">",
"     40",
"    </a>",
"    ]. To abort the cycle, the bleeding area is tightly packed [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27336/abstract/41\">",
"     41",
"    </a>",
"    ] and the wound dressed, but left open, and the patient is transferred to an intensive care unit for continuous monitoring, replacement of appropriate blood products, and correction of physiologic derangements (\"damage control\"). This approach halts the downward spiral and lessens the risk of abdominal compartment syndrome. Compartment syndrome is more difficult to define postpartum since postcesarean intraabdominal pressure appears to be higher than in the general surgical population, especially in women with elevated body mass index and hypertensive disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27336/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20761?source=see_link\">",
"     \"Abdominal compartment syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The author uses a sufficient number of gauze bandages (eg, Kerlix) tied end-to-end to pack the pelvis tightly and tamponade the hemorrhage. The free end of the gauze train is extracorporealized through the main incision. The peritoneum, muscle, and fascia are closed in the usual fashion, but with the gauze protruding from one end of the incision. The subcutaneous and cutaneous layers are left open and packed with additional gauze.",
"   </p>",
"   <p>",
"    Different surgeons practice slight variations of this procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27336/abstract/41,43-52\">",
"     41,43-52",
"    </a>",
"    ]. One variation is to fill a sterile plastic bag (eg, drawstring bag used to cover x-ray film) or cloth container with gauze and place it against the pelvic bleeders. The drawstrings are pulled through the vagina and attached to a weight, which provides traction so that the pack exerts pressure against the pelvic floor.",
"   </p>",
"   <p>",
"    The need for &ge;2 units packed RBCs per hour for three hours is a sign of significant ongoing bleeding and need for surgical intervention or arterial embolization by an interventional radiologist.",
"   </p>",
"   <p>",
"    Otherwise, the patient is returned to the operating room to undergo definitive surgical care in 48 hours. Packing should not be removed until coagulation defects have been corrected. If the packing has controlled bleeding, it generally is removed at this time. If it is removed too soon, bleeding will resume, whereas if it is removed too late, pelvic infection or abscess may ensue.",
"   </p>",
"   <p>",
"    Under general anesthesia, the wound is opened and the gauze is removed with gentle traction. The pelvis is irrigated with saline to clear loose clots and other debris, but aggressive exploration of the pelvis is not performed if no pooling of blood is noted. The wound is then reapproximated in the usual manner.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Recombinant activated factor VIIa",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human recombinant factor VIIa has been approved by the United States Food and Drug Administration for treatment of individuals with bleeding related to hemophilia A and B inhibitors, acquired inhibitors, and congenital factor VII deficiency. It has also been used successfully off-label for control of bleeding in other situations, such as intractable bleeding associated with postpartum uterine atony, placenta accreta, or uterine rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27336/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. This therapy appears promising when standard therapy fails [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27336/abstract/54,55\">",
"     54,55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Doses of 16.7 to 120",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    as a single bolus injection over a few minutes every two hours until hemostasis is achieved have been effective, and usually control bleeding within 10 to 40 minutes of the first dose [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27336/abstract/53,56\">",
"     53,56",
"    </a>",
"    ]. However, the appropriate dose of rFVIIa may be quite different, depending on the levels of other coagulation factors present. As an example, a case report of bleeding despite administration of rFVIIa for PPH attributed the failure to the patient's low fibrinogen level (&lt;60",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27336/abstract/57\">",
"     57",
"    </a>",
"    ]. The authors suggested aggressive therapy with standard blood components should be undertaken before giving rFVIIa. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31962?source=see_link\">",
"     \"Therapeutic uses of recombinant coagulation factor VIIa\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The drug is very expensive (about $1 per mcg) and may increase the risk of thromboembolism, thus it should be reserved for cases of intractable hemorrhage and coagulopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE UTERINE HEMORRHAGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemorrhage may not be appreciated before the abdomen has been closed or before the patient has been moved out of the operating room. It may manifest as excessive vaginal bleeding or as hypotension, tachycardia,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    low urine output from hypovolemia.",
"   </p>",
"   <p>",
"    If excessive vaginal bleeding is present, the cervix and vagina should be inspected and lacerations repaired under adequate . If the uterus is boggy, the diagnosis of uterine atony is made.",
"   </p>",
"   <p>",
"    The initial management of uterine atony after cesarean delivery is similar to that after vaginal delivery and consists of:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fundal massage to contract the uterus",
"     </li>",
"     <li>",
"      Administration of uterotonic drugs",
"     </li>",
"     <li>",
"      Fluid resuscitation and transfusion",
"     </li>",
"     <li>",
"      Laboratory tests to evaluate blood loss and coagulopathy and type and cross for multiple units of packed red blood cells",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If excessive bleeding persists, uterine artery embolization is an option for stable patients in whom volume status can be maintained until the procedure can be completed (approximately two hours). Laparotomy is indicated in patients with massive bleeding and those who are unstable since is unlikely that replacement of blood products will match blood loss in these patients.",
"   </p>",
"   <p>",
"    These procedures are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/60/41929?source=see_link\">",
"     \"Management of postpartum hemorrhage at vaginal delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    PPH more than 24 hours postpartum is termed secondary PPH. Causes and management are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/38/42600?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of postpartum hemorrhage\", section on 'Secondary postpartum hemorrhage'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/15/38129?source=see_link\">",
"       \"Patient information: Postpartum hemorrhage (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The initial management of postpartum hemorrhage (PPH) at cesarean delivery includes: fundal massage and uterotonic drugs for treatment of uterine atony, fluid resuscitation and transfusion, laboratory tests to evaluate blood loss and coagulopathy, and inspection for and repair of lacerations and incisional bleeding. Placenta attachment abnormalities require additional interventions. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Initial management'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/7/8311?source=see_link\">",
"       \"Clinical features and diagnosis of placenta accreta, increta, and percreta\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If these measures do not control hemorrhage, we suggest uterine artery ligation as the first-line surgical approach (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Uterine artery and utero-ovarian artery ligation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If bleeding from uterine atony is not controlled by uterine artery ligation, we suggest use of a uterine compression suture technique (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Uterine compression sutures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hysterectomy is a last resort, but should not be delayed in women who have disseminated intravascular coagulation and require prompt control of uterine hemorrhage to prevent death. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Hysterectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with persistent severe hemorrhage can enter a lethal downward spiral characterized by hypothermia, coagulopathy, and metabolic acidosis. To abort the cycle, the bleeding area is tightly packed and the wound dressed, but left open, and the patient is transferred to an intensive care unit for continuous monitoring, replacement of appropriate blood products, and correction of physiologic derangements. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Pelvic packing'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27336/abstract/1\">",
"      Charbit B, Mandelbrot L, Samain E, et al. The decrease of fibrinogen is an early predictor of the severity of postpartum hemorrhage. J Thromb Haemost 2007; 5:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27336/abstract/2\">",
"      O'Leary JL, O'Leary JA. Uterine artery ligation in the control of intractable postpartum hemorrhage. Am J Obstet Gynecol 1966; 94:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27336/abstract/3\">",
"      O'Leary JA. Uterine artery ligation in the control of postcesarean hemorrhage. J Reprod Med 1995; 40:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27336/abstract/4\">",
"      AbdRabbo SA. Stepwise uterine devascularization: a novel technique for management of uncontrolled postpartum hemorrhage with preservation of the uterus. Am J Obstet Gynecol 1994; 171:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27336/abstract/5\">",
"      Sentilhes L, Trichot C, Resch B, et al. Fertility and pregnancy outcomes following uterine devascularization for severe postpartum haemorrhage. Hum Reprod 2008; 23:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27336/abstract/6\">",
"      Roman H, Sentilhes L, Cingotti M, et al. Uterine devascularization and subsequent major intrauterine synechiae and ovarian failure. Fertil Steril 2005; 83:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27336/abstract/7\">",
"      Evans S, McShane P. The efficacy of internal iliac artery ligation in obstetric hemorrhage. Surg Gynecol Obstet 1985; 160:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27336/abstract/8\">",
"      Joshi VM, Otiv SR, Majumder R, et al. Internal iliac artery ligation for arresting postpartum haemorrhage. BJOG 2007; 114:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27336/abstract/9\">",
"      Gottlieb AG, Pandipati S, Davis KM, Gibbs RS. Uterine necrosis: a complication of uterine compression sutures. Obstet Gynecol 2008; 112:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27336/abstract/10\">",
"      B-Lynch C. Partial ischemic necrosis of the uterus following a uterine brace compression suture. BJOG 2005; 112:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27336/abstract/11\">",
"      Joshi VM, Shrivastava M. Partial ischemic necrosis of the uterus following a uterine brace compression suture. BJOG 2004; 111:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27336/abstract/12\">",
"      Reyftmann L, Nguyen A, Ristic V, et al. [Partial uterine wall necrosis following Cho hemostatic sutures for the treatment of postpartum hemorrhage]. Gynecol Obstet Fertil 2009; 37:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27336/abstract/13\">",
"      El-Hamamy E. Partial ischemic necrosis of the uterus following a uterine brace compression suture. BJOG 2005; 112:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27336/abstract/14\">",
"      Pechtor K, Richards B, Paterson H. Antenatal catastrophic uterine rupture at 32 weeks of gestation after previous B-Lynch suture. BJOG 2010; 117:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27336/abstract/15\">",
"      Poujade O, Grossetti A, Mougel L, et al. Risk of synechiae following uterine compression sutures in the management of major postpartum haemorrhage. BJOG 2011; 118:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27336/abstract/16\">",
"      Baskett TF. Uterine compression sutures for postpartum hemorrhage: efficacy, morbidity, and subsequent pregnancy. Obstet Gynecol 2007; 110:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27336/abstract/17\">",
"      Kayem G, Kurinczuk JJ, Alfirevic Z, et al. Uterine compression sutures for the management of severe postpartum hemorrhage. Obstet Gynecol 2011; 117:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27336/abstract/18\">",
"      B-Lynch C, Coker A, Lawal AH, et al. The B-Lynch surgical technique for the control of massive postpartum haemorrhage: an alternative to hysterectomy? Five cases reported. Br J Obstet Gynaecol 1997; 104:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27336/abstract/19\">",
"      Ferguson JE, Bourgeois FJ, Underwood PB. B-Lynch suture for postpartum hemorrhage. Obstet Gynecol 2000; 95:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27336/abstract/20\">",
"      Allam MS, B-Lynch C. The B-Lynch and other uterine compression suture techniques. Int J Gynaecol Obstet 2005; 89:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27336/abstract/21\">",
"      Sentilhes L, Gromez A, Razzouk K, et al. B-Lynch suture for massive persistent postpartum hemorrhage following stepwise uterine devascularization. Acta Obstet Gynecol Scand 2008; 87:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27336/abstract/22\">",
"      Smith KL, Baskett TF. Uterine compression sutures as an alternative to hysterectomy for severe postpartum hemorrhage. J Obstet Gynaecol Can 2003; 25:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27336/abstract/23\">",
"      Hayman RG, Arulkumaran S, Steer PJ. Uterine compression sutures: surgical management of postpartum hemorrhage. Obstet Gynecol 2002; 99:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27336/abstract/24\">",
"      Ghezzi F, Cromi A, Uccella S, et al. The Hayman technique: a simple method to treat postpartum haemorrhage. BJOG 2007; 114:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27336/abstract/25\">",
"      Pereira A, Nunes F, Pedroso S, et al. Compressive uterine sutures to treat postpartum bleeding secondary to uterine atony. Obstet Gynecol 2005; 106:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27336/abstract/26\">",
"      Ouahba J, Piketty M, Huel C, et al. Uterine compression sutures for postpartum bleeding with uterine atony. BJOG 2007; 114:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27336/abstract/27\">",
"      Cho JH, Jun HS, Lee CN. Hemostatic suturing technique for uterine bleeding during cesarean delivery. Obstet Gynecol 2000; 96:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27336/abstract/28\">",
"      Nelson GS, Birch C. Compression sutures for uterine atony and hemorrhage following cesarean delivery. Int J Gynaecol Obstet 2006; 92:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27336/abstract/29\">",
"      Hackethal A, Brueggmann D, Oehmke F, et al. Uterine compression U-sutures in primary postpartum hemorrhage after Cesarean section: fertility preservation with a simple and effective technique. Hum Reprod 2008; 23:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27336/abstract/30\">",
"      Zheng J, Xiong X, Ma Q, et al. A new uterine compression suture for postpartum haemorrhage with atony. BJOG 2011; 118:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27336/abstract/31\">",
"      Alouini S, Coly S, M&eacute;gier P, et al. Multiple square sutures for postpartum hemorrhage: results and hysteroscopic assessment. Am J Obstet Gynecol 2011; 205:335.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27336/abstract/32\">",
"      Taylor A, Sharma M, Tsirkas P, et al. Reducing blood loss at open myomectomy using triple tourniquets: a randomised controlled trial. BJOG 2005; 112:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27336/abstract/33\">",
"      Rebarber A, Lonser R, Jackson S, et al. The safety of intraoperative autologous blood collection and autotransfusion during cesarean section. Am J Obstet Gynecol 1998; 179:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27336/abstract/34\">",
"      Rainaldi MP, Tazzari PL, Scagliarini G, et al. Blood salvage during caesarean section. Br J Anaesth 1998; 80:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27336/abstract/35\">",
"      Liumbruno GM, Meschini A, Liumbruno C, Rafanelli D. The introduction of intra-operative cell salvage in obstetric clinical practice: a review of the available evidence. Eur J Obstet Gynecol Reprod Biol 2011; 159:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27336/abstract/36\">",
"      Liumbruno GM, Liumbruno C, Rafanelli D. Intraoperative cell salvage in obstetrics: is it a real therapeutic option? Transfusion 2011; 51:2244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27336/abstract/37\">",
"      Oei, SG, WInger, CB, Kerkkamp, HE, et al. Cell salvage: how safe in obstetrics? Int J Obstet Anesth 2000; 9:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27336/abstract/38\">",
"      Hess JR, Lawson JH. The coagulopathy of trauma versus disseminated intravascular coagulation. J Trauma 2006; 60:S12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27336/abstract/39\">",
"      Rotondo MF, Zonies DH. The damage control sequence and underlying logic. Surg Clin North Am 1997; 77:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27336/abstract/40\">",
"      Sagraves SG, Toschlog EA, Rotondo MF. Damage control surgery--the intensivist's role. J Intensive Care Med 2006; 21:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27336/abstract/41\">",
"      Dildy GA, Scott JR, Saffer CS, Belfort MA. An effective pressure pack for severe pelvic hemorrhage. Obstet Gynecol 2006; 108:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27336/abstract/42\">",
"      Abdel-Razeq SS, Campbell K, Funai EF, et al. Normative postpartum intraabdominal pressure: potential implications in the diagnosis of abdominal compartment syndrome. Am J Obstet Gynecol 2010; 203:149.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27336/abstract/43\">",
"      Finan MA, Fiorica JV, Hoffman MS, et al. Massive pelvic hemorrhage during gynecologic cancer surgery: \"pack and go back\". Gynecol Oncol 1996; 62:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27336/abstract/44\">",
"      Ghourab S, Al-Nuaim L, Al-Jabari A, et al. Abdomino-pelvic packing to control severe haemorrhage following caesarean hysterectomy. J Obstet Gynaecol 1999; 19:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27336/abstract/45\">",
"      Awonuga AO, Merhi ZO, Khulpateea N. Abdominal packing for intractable obstetrical and gynecologic hemorrhage. Int J Gynaecol Obstet 2006; 93:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27336/abstract/46\">",
"      Howard RJ, Straughn JM Jr, Huh WK, Rouse DJ. Pelvic umbrella pack for refractory obstetric hemorrhage secondary to posterior uterine rupture. Obstet Gynecol 2002; 100:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27336/abstract/47\">",
"      Burchell RC. The umbrella pack to control pelvic hemorrhage. Conn Med 1968; 32:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27336/abstract/48\">",
"      PARENTE JT, DLUGI H, WEINGOLD AB. Pelvic hemostasis: a new technic and pack. Obstet Gynecol 1962; 19:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27336/abstract/49\">",
"      Cassels JW Jr, Greenberg H, Otterson WN. Pelvic tamponade in puerperal hemorrhage. A case report. J Reprod Med 1985; 30:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27336/abstract/50\">",
"      Robie GF, Morgan MA, Payne GG Jr, Wasemiller-Smith L. Logothetopulos pack for the management of uncontrollable postpartum hemorrhage. Am J Perinatol 1990; 7:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27336/abstract/51\">",
"      Hallak M, Dildy GA 3rd, Hurley TJ, Moise KJ Jr. Transvaginal pressure pack for life-threatening pelvic hemorrhage secondary to placenta accreta. Obstet Gynecol 1991; 78:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27336/abstract/52\">",
"      Dildy, GA, Scott, JR, Saffer, CS, Belfort, MA. Pelvic pressure pack for catastrophic postpartum hemorrhage. Obstet Gynecol 2000; 95:S7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27336/abstract/53\">",
"      Franchini M, Lippi G, Franchi M. The use of recombinant activated factor VII in obstetric and gynaecological haemorrhage. BJOG 2007; 114:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27336/abstract/54\">",
"      Phillips LE, McLintock C, Pollock W, et al. Recombinant activated factor VII in obstetric hemorrhage: experiences from the Australian and New Zealand Haemostasis Registry. Anesth Analg 2009; 109:1908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27336/abstract/55\">",
"      Welsh A, McLintock C, Gatt S, et al. Guidelines for the use of recombinant activated factor VII in massive obstetric haemorrhage. Aust N Z J Obstet Gynaecol 2008; 48:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27336/abstract/56\">",
"      Alfirevic Z, Elbourne D, Pavord S, et al. Use of recombinant activated factor VII in primary postpartum hemorrhage: the Northern European registry 2000-2004. Obstet Gynecol 2007; 110:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27336/abstract/57\">",
"      Lewis NR, Brunker P, Lemire SJ, Kaufman RM. Failure of recombinant factor VIIa to correct the coagulopathy in a case of severe postpartum hemorrhage. Transfusion 2009; 49:689.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6712 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-199.231.185.123-3EAB60D91F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_44_27336=[""].join("\n");
var outline_f26_44_27336=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      INITIAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      INTRAOPERATIVE INTERVENTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Uterine artery and utero-ovarian artery ligation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Internal iliac artery ligation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Uterine compression sutures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - B-Lynch suture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Other techniques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Balloon tamponade",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Post-laparotomy inspection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19762763\">",
"      Management of diffuse oozing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      TEMPORIZING MEASURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Aortic compression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19762787\">",
"      Uterine tourniquet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Intraoperative cell salvage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Pelvic packing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Recombinant activated factor VIIa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      POSTOPERATIVE UTERINE HEMORRHAGE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/6712\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6712|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/32/6657\" title=\"figure 1\">",
"      Uterine artery ligation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/22/356\" title=\"figure 2\">",
"      B-Lynch suture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/48/36623\" title=\"figure 3\">",
"      Hayman stitch",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/44/4800\" title=\"figure 4\">",
"      Pereira stitch",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/7/27775\" title=\"figure 5\">",
"      Cho stitch",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/44/16069\" title=\"figure 6\">",
"      Ureter and blood vessels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/34/13859\" title=\"figure 7\">",
"      Ureter and uterine artery",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20761?source=related_link\">",
"      Abdominal compartment syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/7/8311?source=related_link\">",
"      Clinical features and diagnosis of placenta accreta, increta, and percreta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/57/29592?source=related_link\">",
"      Diagnostic cystourethroscopy for gynecologic conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22711?source=related_link\">",
"      Intrauterine balloon tamponade for control of postpartum hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/18/43305?source=related_link\">",
"      Management of hemorrhage in gynecologic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/60/41929?source=related_link\">",
"      Management of postpartum hemorrhage at vaginal delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/38/42600?source=related_link\">",
"      Overview of postpartum hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/15/38129?source=related_link\">",
"      Patient information: Postpartum hemorrhage (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/43/29367?source=related_link\">",
"      Peripartum hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/27/41400?source=related_link\">",
"      Surgical female pelvic anatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/54/10088?source=related_link\">",
"      Techniques to reduce blood loss during abdominal or laparoscopic myomectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31962?source=related_link\">",
"      Therapeutic uses of recombinant coagulation factor VIIa",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_44_27337="Role of oxidative stress in heart failure";
var content_f26_44_27337=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Role of oxidative stress in heart failure",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/44/27337/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/44/27337/contributors\">",
"     Michael M Givertz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/44/27337/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/44/27337/contributors\">",
"     Wilson S Colucci, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/44/27337/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/44/27337/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/44/27337/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oxidant byproducts, such as superoxide anion (O2-) and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    , are produced in the body as a consequence of normal aerobic metabolism. These molecules are highly reactive with other biologic molecules, and are referred to as reactive oxygen species (ROS) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/1\">",
"     1",
"    </a>",
"    ]. Under normal physiologic conditions, the production of oxygen free radicals and peroxides is balanced by an efficient system of antioxidants, which are molecules capable of \"scavenging\" ROS, thereby preventing oxidative damage [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/2\">",
"     2",
"    </a>",
"    ]. Naturally occurring antioxidants are of several types.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At the cellular level, enzymatic antioxidants, such as superoxide dismutase (SOD) and catalase, play an important role in the conversion of ROS to oxygen and water.",
"     </li>",
"     <li>",
"      Several nonenzymatic antioxidants are also important in scavenging free radicals. Included in this group are the lipid-soluble antioxidants alpha tocopherol (vitamin E) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/50/21283?source=see_link\">",
"       beta-carotene",
"      </a>",
"      , and the water-soluble antioxidants ascorbic acid (vitamin C) and glutathione. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26456?source=see_link\">",
"       \"Nutritional antioxidants in coronary heart disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In pathologic states free radicals may be present in relative excess. This shift of the balance in favor of oxidation, termed \"oxidative stress,\" may have detrimental effects on cellular and tissue function, contributing to the pathogenesis of a wide variety of disease states, including heart failure (HF), atherosclerosis, and cancer, and to the normal process of aging [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. This topic will discuss the role of oxidative stress in HF [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ROLE OF OXIDATIVE STRESS IN MYOCARDIAL FAILURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of experimental observations have raised the possibility that oxidative stress may play a role in the development of myocardial failure.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mechanical stretch of a rat papillary muscle can induce myocyte apoptosis and the generation of ROS [",
"      <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Peroxynitrite, the product of nitric oxide and superoxide anion, can cause myocyte injury and death [",
"      <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/8,9\">",
"       8,9",
"      </a>",
"      ]. This injury can be reversed by the free radical scavenger SOD [",
"      <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Isoprostanes, which are bioactive prostaglandin-like compounds that are formed by free radical-catalyzed peroxidation of arachidonic acid, are potent vasoconstrictors. In the isolated pig heart, cyclooxygenase inhibitors increase the amount of isoprostanes and exacerbate the loss of cardiac function due to ischemia-reperfusion injury [",
"      <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      O2- reduces calcium-activated force of contraction in skinned rat trabeculae [",
"      <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      ROS may deplete the myocardium of antioxidants [",
"      <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/12\">",
"       12",
"      </a>",
"      ] and may contribute to myocyte injury resulting from ischemia-reperfusion [",
"      <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/13\">",
"       13",
"      </a>",
"      ] and anthracycline cardiotoxicity [",
"      <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/14\">",
"       14",
"      </a>",
"      ], and in the transition from hypertrophy to HF [",
"      <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/15\">",
"       15",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=see_link\">",
"       \"Cardiotoxicity of anthracycline-like chemotherapy agents\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These experimental findings suggest that oxygen-derived free radicals can exert direct toxic effects on myocardial structure and function and that free radical scavengers (eg, antioxidants) may reverse these effects. Other experimental studies have evaluated the effect of ROS in heart failure, while the data in humans are more limited.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Animal studies of oxidative stress and heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of observations support the hypothesis that oxidative stress contributes to the development of HF. Both increased oxidative stress and reduced availability of protective factors may play a role [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/16-19\">",
"     16-19",
"    </a>",
"    ]. With respect to the latter, reductions in SOD activity, catalase, and glutathione have been associated with failing myocardium [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. There is also upregulation of catalase gene expression, possibly as an adaptive cardioprotective response to the chronic pathophysiologic condition [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The antioxidant deficit and increased oxidative stress (as estimated from myocardial lipid peroxidation) developing in HF due to myocardial infarction occur first in the left ventricle and then in the right ventricle; these changes correlate with ventricular function [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/17\">",
"     17",
"    </a>",
"    ]. Afterload reduction with an angiotensin converting enzyme inhibitor in this setting is associated with an improvement in antioxidant activity and a decline in lipid peroxidation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Further support for the importance of protective factors is the observation that transgenic mice that lack mitochondrial SOD die early in life from dilated cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/18\">",
"     18",
"    </a>",
"    ]. In contrast, mice that overexpress glutathione peroxidase (which protects against oxidative stress) have less left ventricular dilation and dysfunction and increased survival after coronary ligation compared to controls [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/21\">",
"     21",
"    </a>",
"    ]. Another study in transgenic mice showed that induction of heme oxygenase-1 in failing hearts opposes pathologic LV remodeling in part through decreased oxidative stress [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subsequent experimental studies have focused on elucidating the mechanisms underlying increased oxidative stress in HF:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment of adult rat ventricular myocytes with tumor necrosis factor alpha causes generation of reactive oxygen species and increases mitochondrial DNA damage [",
"      <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Mice with high-output HF due to an arteriovenous fistula demonstrate increased activity of myocardial matrix metalloproteinases and NADPH oxidase that can be prevented by administration of a cardiac inhibitor of metalloproteinase [",
"      <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Toll-like receptor-2 knockout mice are protected against oxidative stress-mediated cardiac remodeling and failure and have improved survival following experimental myocardial infarction [",
"      <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Rabbits with pacing-induced HF demonstrate increased oxidative stress as evidenced by decreased myocardial reduced-to-oxidized glutathione ratio and myocyte apoptosis, and activation of myocardial mitogen activated protein kinase [",
"      <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Oxidative stress in human heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is in vivo data suggesting that oxidative stress is increased in patients with chronic HF and may predict outcome. Elevated plasma levels of malondialdehyde-like activity (MDA), a marker of lipid peroxidation, have been demonstrated in patients with ischemic and nonischemic cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. The values have generally correlated inversely with the left ventricular ejection fraction (LVEF) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/29\">",
"     29",
"    </a>",
"    ] and directly with the chronicity and severity of HF symptoms and reduction in functional capacity [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. An elevated level of oxidized low density lipoprotein, another marker of oxidative stress, is predictive of mortality in patients with HF [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/33\">",
"     33",
"    </a>",
"    ]. However, in the Prospective Randomized",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"     Amlodipine",
"    </a>",
"    Survival Evaluation 2 (PRAISE-2) trial, there was no relationship between plasma levels of malondialdehyde and survival in patients with nonischemic cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most studies evaluating oxidative stress in HF have been limited by a variety of factors. These include small numbers, nonspecific methods for measuring oxidative stress, and lack of control for medications, vitamins, and other risk factors associated with oxidative stress, such as smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In an attempt to more accurately assess oxidative stress, a superior technique has been developed which involves measuring stable end products of lipid peroxidation known as F2-isoprostanes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/36\">",
"     36",
"    </a>",
"    ]. In one study of 51 patients with HF undergoing cardiac surgery, pericardial fluid levels of 8-iso-prostaglandin F2-alpha were elevated and correlated with HF severity [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/37\">",
"     37",
"    </a>",
"    ]. In a subgroup of patients who underwent preoperative echocardiography, pericardial 8-iso-PGF2-alpha correlated with left ventricular end-diastolic dimension. F2-isoprostane levels are also increased in the plasma of patients with:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      chronic heart failure in relation to disease severity, and inversely correlate with ejection fraction [",
"      <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/38\">",
"       38",
"      </a>",
"      ], and",
"     </li>",
"     <li>",
"      acute coronary syndromes, and predict adverse outcomes including HF and 30-day mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other markers of in vivo oxidative stress in humans have also been described:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Biopyrrins are oxidative metabolites of bilirubin. In a study of 94 patients with decompensated HF, the urinary biopyrrin-to-creatinine ratio correlated with symptoms and with BNP levels, and decreased with treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Endothelium-bound extracellular SOD activity is decreased and xanthine oxidase activity is increased in patients with chronic HF [",
"      <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/41\">",
"       41",
"      </a>",
"      ]. These abnormalities correlated with impaired endothelium-dependent vasodilation.",
"     </li>",
"     <li>",
"      Nitrotyrosine immunoreactivity is an intracellular marker of oxidative stress. In patients with acute decompensated heart failure, nitrotyrosine immunoreactivity measured ex-vivo in venous endothelial cells is increased in association with abnormal flow-mediated dilation and decreases with return to a compensated state [",
"      <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hydroxyl radical (*OH) production can be probed by giving intravenous lysine acetylsalicylate and determining the 2,3-dihydorxybenzoic",
"      <span class=\"nowrap\">",
"       acid/salicylic",
"      </span>",
"      acid",
"      <span class=\"nowrap\">",
"       (DHBA/SA)",
"      </span>",
"      ratio. In a pilot study of patients with ST segment elevation myocardial infarction, *OH production peaked at 24 hours and remained elevated in a subset of patients who developed heart failure [",
"      <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Xanthine oxidase (XO) generates superoxide anion and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"       hydrogen peroxide",
"      </a>",
"      as byproducts. Serum uric acid (UA) levels reflect the degree of XO activation, rise in parallel with New York Heart Association functional class, and independently predict survival in patients with chronic HF [",
"      <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/44\">",
"       44",
"      </a>",
"      ]. UA levels may also predict incident HF [",
"      <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/45\">",
"       45",
"      </a>",
"      ]. Allantoin results from further oxidation of UA and has been shown to be 75 percent higher in hyperuricemic HF patients compared to healthy controls [",
"      <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/46\">",
"       46",
"      </a>",
"      ]. Myocardial XO activity is increased in patients with chronic mitral regurgitation and normal LV function undergoing mitral valve surgery, and may contribute to myofibrillar degeneration and postoperative contractile dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/47\">",
"       47",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Myocardial NADPH oxidase activity is increased in end-stage failing hearts explanted at the time of cardiac transplantation compared to nonfailing control hearts [",
"      <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/48\">",
"       48",
"      </a>",
"      ]. Electroparamagnetic resonance (EPR) with spin trapping has also been used to demonstrate increased levels of O2- in failing human hearts [",
"      <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Myocardial expression of 4-hydroxy-2-nonenal (HNE)-modified protein, which is a major lipid peroxidation product, is increased in biopsy samples from patients with hypertrophic cardiomyopathy compared to controls and inversely correlates with ejection fraction [",
"      <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Myocardial phosphodiesterase (PDE)-5 protein expression is increased 4.5 fold in end-stage heart failure and correlates with markers of oxidative stress such as 3-nitrotryosine and 4-hydoxynonenal expression.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"       Sildenafil",
"      </a>",
"      , a PDE-5 inhibitor, may improve contractile function by reducing myocardial oxidative stress [",
"      <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Potential mechanisms for increased oxidative stress in chronic HF include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Decreased myocardial antioxidant activity [",
"      <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Free radical generation during prostaglandin biosynthesis",
"     </li>",
"     <li>",
"      Autooxidation of catecholamines [",
"      <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/52\">",
"       52",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Repetitive ischemia and reperfusion [",
"      <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/53\">",
"       53",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Activation of proinflammatory cytokines [",
"      <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/23\">",
"       23",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Increased activity of xanthine oxidase [",
"      <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/54\">",
"       54",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Thiamine deficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Post-translational modification in the ubiquitin proteasome system [",
"      <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/56\">",
"       56",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Reduced availability of L-arginine [",
"      <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/57\">",
"       57",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, risk factors for cardiovascular disease such as hypertension, diabetes, and obesity have been associated with increased oxidative stress [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/58-60\">",
"     58-60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ROLE OF ANTIOXIDANTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from animal and human physiology studies suggest that antioxidant therapy improves a number of measures of cardiovascular function. However, randomized trials of antioxidants have shown no improvement in important clinical outcomes, and in one trial, outcomes were worse in patients treated with vitamin E. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26456?source=see_link\">",
"     \"Nutritional antioxidants in coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Specific agents",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Vitamin C",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ascorbic acid (vitamin C) is the most important of the natural occurring water soluble antioxidants [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/61\">",
"     61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/62/28650?source=see_link\">",
"     \"Overview of water-soluble vitamins\"",
"    </a>",
"    .) It protects plasma lipids from peroxidation, scavenges ROS, and plays a role in the recycling of alpha tocopherol. Supplementation with 1000",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    achieves maximal plasma ascorbate concentrations because of the gastrointestinal threshold for absorption and the renal threshold for excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/62\">",
"     62",
"    </a>",
"    ]; it also provides significant protection from lipid peroxidation when combined with alpha tocopherol [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acute intravenous administration of ascorbic acid has been shown to reduce markers of oxidative stress, improve endothelial dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/64\">",
"     64",
"    </a>",
"    ] and potentiate the natriuretic effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/65\">",
"     65",
"    </a>",
"    ]. In patients with mild-moderate heart failure post myocardial infarction, IV ascorbic acid improved myocardial oxygen efficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/66\">",
"     66",
"    </a>",
"    ]. However, while acute intracoronary administration of ascorbic acid potentiated the contractile response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    in healthy controls, it had no effect in HF [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chronic oral administration of ascorbic acid improves flow-mediated dilation in patients with symptomatic left ventricular dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/68\">",
"     68",
"    </a>",
"    ]. Ascorbic acid also reduces oxidative stress and free radical activity in these patients; however, there is no correlation between the changes in endothelial function and oxidative stress, suggesting that there may be other non-antioxidant effects of vitamin C&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Vitamin E",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alpha tocopherol (vitamin E) is an important component of the low-density lipoprotein (LDL) particle and its lipid solubility allows it to enter the vessel wall to scavenge free radicals [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/63\">",
"     63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/12/28871?source=see_link\">",
"     \"Overview of vitamin E\"",
"    </a>",
"    .) Alpha tocopherol also inhibits smooth muscle cell proliferation, reduces platelet aggregation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/70\">",
"     70",
"    </a>",
"    ], and, when given at a dose of 800",
"    <span class=\"nowrap\">",
"     IU/day,",
"    </span>",
"    significantly limits the oxidative modification of low density lipoprotein which is an important proatherogenic particle [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/71\">",
"     71",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18138?source=see_link\">",
"     \"Lipoprotein classification; metabolism; and role in atherosclerosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Probucol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Probucol, originally developed as a lipid-lowering agent, possesses potent antioxidant properties and prevents oxidative modification of LDL. In animal and human studies, probucol prevents endothelial dysfunction and slows the progression of atherosclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. Protective antioxidant effects of probucol have also been demonstrated in animal models of diabetic and adriamycin-induced cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/74\">",
"     74",
"    </a>",
"    ]. Probucol also prevents ventricular remodeling, and attenuates myocardial oxidative stress in dogs with pacing-induced HF and in rats after myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/75\">",
"     75",
"    </a>",
"    ]. Probucol prolongs the QT interval and is no longer available for clinical use in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Coenzyme Q10",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coenzyme Q10 is a vitamin-like, fat soluble quinone found in high concentrations in the mitochondria of the heart, liver, and kidney, where it is involved in electron and proton transfer during oxidative phosphorylation. It is also an antioxidant and free radical scavenger with membrane stabilizing properties. Myocardial biopsies from patients with HF have demonstrated depletion of coenzyme Q10, suggesting that this may play a role in the development of HF. One randomized, double-blind crossover trial of 30 patients found that, compared to placebo, three months of therapy with coenzyme Q10 had no effect on LVEF, cardiac volumes or hemodynamics, or quality of life indices [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/76\">",
"     76",
"    </a>",
"    ]. A second trial randomly assigned 55 patients with moderate-severe HF to coenzyme Q10 or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/77\">",
"     77",
"    </a>",
"    ]. After six months, ejection fraction and peak oxygen consumption did not improve in either group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Allopurinol",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"     Allopurinol",
"    </a>",
"    inhibits xanthine oxidase in the vascular endothelium and can prevent the formation of superoxide free radicals. In patients with HF, allopurinol has been shown to reduce markers of oxidative stress and improve endothelium-dependent vasodilation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/78\">",
"     78",
"    </a>",
"    ], independent of its effects on lowering serum uric acid levels [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/79\">",
"     79",
"    </a>",
"    ]. In addition, experimental models suggest that oxidant stress resulting from xanthine oxidase activation contributes to mechanoenergetic uncoupling, and that xanthine oxidase inhibition with allopurinol may improve left ventricular efficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/80\">",
"     80",
"    </a>",
"    ]. In rats with heart failure, chronic xanthine oxidase inhibition causes reverse ventricular remodeling [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/81\">",
"     81",
"    </a>",
"    ]. In a study of nine patients with dilated cardiomyopathy, allopurinol infused into the left main coronary artery increased myocardial efficiency (defined as the ratio of stroke work to myocardial oxygen consumption) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/80\">",
"     80",
"    </a>",
"    ]. A later randomized study in 16 patients with nonischemic cardiomyopathy showed that intravenous allopurinol increased ATP energy delivery in failing human myocardium [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Allicin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allicin is an organosulfur compound derived from garlic. Animal studies have shown potential cardiovascular health benefits of allicin, including reduction in blood pressure, atherosclerosis and fat deposition through anti-thrombotic and anti-inflammatory pathways. In cardiac myocytes isolated from a rat model of hypertrophy and failure, allicin inhibited hypertrophic responses induced by angiotensin II or pressure overload and suppressed ROS generation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/83\">",
"     83",
"    </a>",
"    ]. Sufenic acid, which is produced by the decomposition of allicin, rapidly reacts with free radicals and is felt to be responsible for the anti-oxidant properties of garlic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Heart failure medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"     Carvedilol",
"    </a>",
"    , a beta blocker that has vasodilating effects, exerts antioxidant activity in vitro; the apparent mechanism of carvedilol's inhibition of lipid peroxidation is mainly via scavenging free radicals [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/84\">",
"     84",
"    </a>",
"    ]. One clinical trial that compared carvedilol with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    in 67 patients with HF found that both agents increased ejection fraction over six months and had a similar degree of antioxidant activity, determined by measuring levels of thiobarbituric acid-reactive substances (an indirect marker of free radical activity) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In another study, increased expression of HNE-modified protein, a major lipid peroxidation product, was demonstrated in endomyocardial biopsy specimens from patients with dilated cardiomyopathy compared to controls [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/86\">",
"     86",
"    </a>",
"    ]. After treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    for a mean of nine months, HF improved and myocardial HNE-modified protein levels decreased by 40 percent. Other controlled trials have failed to show antioxidant effects of carvedilol in heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other cardiovascular agents that have been shown to exert antioxidant properties in animal models of myocardial injury include the aldosterone receptor antagonists",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/88\">",
"     88",
"    </a>",
"    ] and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5031?source=see_link\">",
"     eplerenone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/89\">",
"     89",
"    </a>",
"    ], and the dihydropyridine calcium antagonist",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/90\">",
"     90",
"    </a>",
"    ]. In vitro studies have also demonstrated that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    is a powerful inhibitor of peroxynitrite formation and dose-dependently inhibits nitration of smooth muscle cell proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/91\">",
"     91",
"    </a>",
"    ]. These properties may explain hydralazine's ability to inhibit nitrate tolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     Metformin",
"    </a>",
"    , a commonly used antidiabetic agent in HF patients with type II diabetes, exerts potent cardioprotective effects against ischemia-reperfusion injury. In dogs with pacing-induced HF, treatment with oral metformin at a dose of 100",
"    <span class=\"nowrap\">",
"     mg/kg/d",
"    </span>",
"    improved LV fractional shortening and reduced LV filling pressures [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/93\">",
"     93",
"    </a>",
"    ]. These beneficial effects were associated with increased phosphorylation of AMP-active protein kinase and endothelial nitric oxide synthase and improved insulin resistance in failing canine hearts.",
"   </p>",
"   <p>",
"    Exercise training has been shown to reduce nitrotyrosine production in skeletal muscle of patients with heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/94\">",
"     94",
"    </a>",
"    ]. However, it is unknown whether local antioxidant effects play an important role in the cardiovascular benefits of exercise training.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Potential therapy for heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;At present, there is no direct evidence that antioxidant therapy or other nutritional supplements reduce morbidity or mortality in patients with HF and their use is not recommended by the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    (class III) (",
"    <a class=\"graphic graphic_table graphicRef81590 \" href=\"UTD.htm?40/1/40989\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Animal studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observations from animal studies suggested that there may be a role for antioxidants as therapy for HF. Among the benefits that have been noted in different models are reduced free radical generation, protection against myocyte damage [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/74\">",
"     74",
"    </a>",
"    ], improved cardiac function after reperfusion injury [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/96,97\">",
"     96,97",
"    </a>",
"    ], prevention of the transition from hypertrophy to HF [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/15\">",
"     15",
"    </a>",
"    ], attenuation of ventricular and vascular remodeling [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/26,75,98\">",
"     26,75,98",
"    </a>",
"    ], and improved survival. In an animal model of pulmonary arterial hypertension and right ventricular failure, treatment with the antioxidant EUK-134 reduced RV oxidative stress, prevented interstitial fibrosis and improved contractile function [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/99\">",
"     99",
"    </a>",
"    ]. In diabetic rats, supplementation with vitamin E improved LV function and significantly attenuated myocardial 8-iso-PGF2-alpha and oxidized glutathione accumulation, suggesting a role for antioxidant therapy in the early stages of diabetic cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Human trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin E and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    have been evaluated in several randomized trials. None have improved outcomes, while patients treated with vitamin E actually had an increased incidence of HF. Clinical trials of ascorbic acid (vitamin C) have also yielded negative results. In a recent study, ascorbic acid improved endothelial function, but worsened skeletal muscle metabolism in HF [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The chronic oral administration of alpha tocopherol (vitamin E) was evaluated in a study of 56 patients with advanced HF that were randomly assigned to receive alpha tocopherol or placebo for 12 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/102\">",
"     102",
"    </a>",
"    ]. Alpha tocopherol had no effect on markers of oxidative stress, neurohormones or quality of life.",
"   </p>",
"   <p>",
"    Of greater concern is recent data from the HOPE-TOO study. This was a report of longer terms outcomes from the earlier HOPE study. The results from HOPE-TOO showed that vitamin E supplementation in patients with vascular disease or diabetes increased the risk of developing heart failure (RR 1.13, 95% CI 1.01-1.26, p = 0.03) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/103\">",
"     103",
"    </a>",
"    ]. In a small study of patients with ischemic cardiomyopathy, vitamin E attenuated the anti-inflammatory effects of statins [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The potential usefulness of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    therapy in HF was evaluated in a study of 11 patients with mild to moderate HF who were randomly assigned to allopurinol 300 mg once daily or placebo for one month [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/78\">",
"     78",
"    </a>",
"    ]. All patients were receiving angiotensin converting enzyme inhibitors and diuretics, and none were taking statins or antioxidant vitamins. Allopurinol significantly increased the forearm blood flow response to acetylcholine, but had no effect on the response to sodium",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"     nitroprusside",
"    </a>",
"    . A subsequent study showed that allopurinol improved endothelial function by reducing vascular oxidative stress and not by lowering uric acid levels [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/79\">",
"     79",
"    </a>",
"    ]. These data suggest that xanthine oxidase inhibition improves endothelial dysfunction in chronic HF.",
"   </p>",
"   <p>",
"    While data from a large, multicenter trial of XO inhibition in heart failure showed no benefit of oxypurinol (600 mg daily) compared to placebo on clinical outcomes in unselected patients with moderate to severe LV dysfunction, there was a trend toward benefit in the subgroup of patients with the highest uric acid levels [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/105\">",
"     105",
"    </a>",
"    ]. Against this background, the NIH Heart Failure Network is currently testing the safety and efficacy of high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    in a high-risk group of hyperuricemic HF patients with reduced LV function [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/106\">",
"     106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to erythropoietic stimulatory effects,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/49/33560?source=see_link\">",
"     darbepoetin alfa",
"    </a>",
"    may have antioxidant properties. Thirty patients with chronic HF and anemia randomized to receive darbepoetin alfa demonstrated improvements in LVEF and six-minute walk distance and reduced BNP levels. In addition, darbepoetin alfa decreased systemic markers of oxidative and nitrosative stress. The percent decrease in nitrotyrosine correlated with the improvement in six-minute walk [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/107\">",
"     107",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The variability in the response to antioxidant therapy may be due to genetic polymorphisms in enzymes involved in oxidative stress [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/108\">",
"     108",
"    </a>",
"    ]. Ongoing research using gene transfer techniques may identify novel ways to increase antioxidant activity in patients with heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?26/44/27337/abstract/109\">",
"     109",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In pathologic states, oxygen free radicals and peroxides may be present in relative excess. This shift of the balance in favor of oxidation, termed \"oxidative stress,\" may have detrimental effects on cellular and tissue function, contributing to the pathogenesis of a wide variety of disease states, including heart failure (HF).",
"     </li>",
"     <li>",
"      Experimental findings suggest that oxygen-derived free radicals can exert direct toxic effects on myocardial structure and function and that free radical scavengers (eg, antioxidants) may reverse these effects.",
"     </li>",
"     <li>",
"      There is in vivo data suggesting that oxidative stress is increased in patients with chronic HF and that markers of oxidative stress may predict outcome.",
"     </li>",
"     <li>",
"      Data from animal and human physiology studies suggest that antioxidant therapy improves a number of measures of cardiovascular structure and function.",
"     </li>",
"     <li>",
"      At present, there is no direct evidence that antioxidant therapy or other nutritional supplements reduce morbidity or mortality in patients with HF and their use is not recommended.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/1\">",
"      Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury: Part I: basic mechanisms and in vivo monitoring of ROS. Circulation 2003; 108:1912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/2\">",
"      Frei B. Reactive oxygen species and antioxidant vitamins: mechanisms of action. Am J Med 1994; 97:5S.",
"     </a>",
"    </li>",
"    <li>",
"     Sies H. Oxidative stress: introductory remarks. In: Oxidative Stress, Sies H (Ed), Academic Press, Orlando 1985. p.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/4\">",
"      Diaz MN, Frei B, Vita JA, Keaney JF Jr. Antioxidants and atherosclerotic heart disease. N Engl J Med 1997; 337:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/5\">",
"      Sawyer DB, Siwik DA, Xiao L, et al. Role of oxidative stress in myocardial hypertrophy and failure. J Mol Cell Cardiol 2002; 34:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/6\">",
"      Korantzopoulos P, Galaris D, Papaioannides D, Siogas K. The possible role of oxidative stress in heart failure and the potential of antioxidant intervention. Med Sci Monit 2003; 9:RA120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/7\">",
"      Cheng W, Li B, Kajstura J, et al. Stretch-induced programmed myocyte cell death. J Clin Invest 1995; 96:2247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/8\">",
"      Lopez BL, Liu GL, Christopher TA, Ma XL. Peroxynitrite, the product of nitric oxide and superoxide, causes myocardial injury in the isolated perfused rat heart. Coron Artery Dis 1997; 8:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/9\">",
"      Pinsky DJ, Cai B, Yang X, et al. The lethal effects of cytokine-induced nitric oxide on cardiac myocytes are blocked by nitric oxide synthase antagonism or transforming growth factor beta. J Clin Invest 1995; 95:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/10\">",
"      M&ouml;bert J, Becker BF. Cyclooxygenase inhibition aggravates ischemia-reperfusion injury in the perfused guinea pig heart: involvement of isoprostanes. J Am Coll Cardiol 1998; 31:1687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/11\">",
"      Gao WD, Liu Y, Marban E. Selective effects of oxygen free radicals on excitation-contraction coupling in ventricular muscle. Implications for the mechanism of stunned myocardium. Circulation 1996; 94:2597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/12\">",
"      Vaage J, Antonelli M, Bufi M, et al. Exogenous reactive oxygen species deplete the isolated rat heart of antioxidants. Free Radic Biol Med 1997; 22:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/13\">",
"      Zweier JL, Rayburn BK, Flaherty JT, Weisfeldt ML. Recombinant superoxide dismutase reduces oxygen free radical concentrations in reperfused myocardium. J Clin Invest 1987; 80:1728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/14\">",
"      Rajagopalan S, Politi PM, Sinha BK, Myers CE. Adriamycin-induced free radical formation in the perfused rat heart: implications for cardiotoxicity. Cancer Res 1988; 48:4766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/15\">",
"      Dhalla AK, Hill MF, Singal PK. Role of oxidative stress in transition of hypertrophy to heart failure. J Am Coll Cardiol 1996; 28:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/16\">",
"      Dhalla AK, Singal PK. Antioxidant changes in hypertrophied and failing guinea pig hearts. Am J Physiol 1994; 266:H1280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/17\">",
"      Hill MF, Singal PK. Right and left myocardial antioxidant responses during heart failure subsequent to myocardial infarction. Circulation 1997; 96:2414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/18\">",
"      Lebovitz RM, Zhang H, Vogel H, et al. Neurodegeneration, myocardial injury, and perinatal death in mitochondrial superoxide dismutase-deficient mice. Proc Natl Acad Sci U S A 1996; 93:9782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/19\">",
"      Khaper N, Singal PK. Effects of afterload-reducing drugs on pathogenesis of antioxidant changes and congestive heart failure in rats. J Am Coll Cardiol 1997; 29:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/20\">",
"      Dieterich S, Bieligk U, Beulich K, et al. Gene expression of antioxidative enzymes in the human heart: increased expression of catalase in the end-stage failing heart. Circulation 2000; 101:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/21\">",
"      Shiomi T, Tsutsui H, Matsusaka H, et al. Overexpression of glutathione peroxidase prevents left ventricular remodeling and failure after myocardial infarction in mice. Circulation 2004; 109:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/22\">",
"      Wang G, Hamid T, Keith RJ, et al. Cardioprotective and antiapoptotic effects of heme oxygenase-1 in the failing heart. Circulation 2010; 121:1912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/23\">",
"      Suematsu N, Tsutsui H, Wen J, et al. Oxidative stress mediates tumor necrosis factor-alpha-induced mitochondrial DNA damage and dysfunction in cardiac myocytes. Circulation 2003; 107:1418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/24\">",
"      Cox MJ, Hawkins UA, Hoit BD, Tyagi SC. Attenuation of oxidative stress and remodeling by cardiac inhibitor of metalloproteinase protein transfer. Circulation 2004; 109:2123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/25\">",
"      Shishido T, Nozaki N, Yamaguchi S, et al. Toll-like receptor-2 modulates ventricular remodeling after myocardial infarction. Circulation 2003; 108:2905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/26\">",
"      Qin F, Shite J, Liang CS. Antioxidants attenuate myocyte apoptosis and improve cardiac function in CHF: association with changes in MAPK pathways. Am J Physiol Heart Circ Physiol 2003; 285:H822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/27\">",
"      McMurray J, McLay J, Chopra M, et al. Evidence for enhanced free radical activity in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1990; 65:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/28\">",
"      McMurray J, Chopra M, Abdullah I, et al. Evidence of oxidative stress in chronic heart failure in humans. Eur Heart J 1993; 14:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/29\">",
"      Belch JJ, Bridges AB, Scott N, Chopra M. Oxygen free radicals and congestive heart failure. Br Heart J 1991; 65:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/30\">",
"      D&iacute;az-V&eacute;lez CR, Garc&iacute;a-Casti&ntilde;eiras S, Mendoza-Ramos E, Hern&aacute;ndez-L&oacute;pez E. Increased malondialdehyde in peripheral blood of patients with congestive heart failure. Am Heart J 1996; 131:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/31\">",
"      Keith M, Geranmayegan A, Sole MJ, et al. Increased oxidative stress in patients with congestive heart failure. J Am Coll Cardiol 1998; 31:1352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/32\">",
"      Nishiyama Y, Ikeda H, Haramaki N, et al. Oxidative stress is related to exercise intolerance in patients with heart failure. Am Heart J 1998; 135:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/33\">",
"      Tsutsui T, Tsutamoto T, Wada A, et al. Plasma oxidized low-density lipoprotein as a prognostic predictor in patients with chronic congestive heart failure. J Am Coll Cardiol 2002; 39:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/34\">",
"      Wijeysundera HC, Hansen MS, Stanton E, et al. Neurohormones and oxidative stress in nonischemic cardiomyopathy: relationship to survival and the effect of treatment with amlodipine. Am Heart J 2003; 146:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/35\">",
"      Morrow JD, Frei B, Longmire AW, et al. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N Engl J Med 1995; 332:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/36\">",
"      Morrow JD, Hill KE, Burk RF, et al. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci U S A 1990; 87:9383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/37\">",
"      Mallat Z, Philip I, Lebret M, et al. Elevated levels of 8-iso-prostaglandin F2alpha in pericardial fluid of patients with heart failure: a potential role for in vivo oxidant stress in ventricular dilatation and progression to heart failure. Circulation 1998; 97:1536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/38\">",
"      Polidori MC, Pratic&oacute; D, Savino K, et al. Increased F2 isoprostane plasma levels in patients with congestive heart failure are correlated with antioxidant status and disease severity. J Card Fail 2004; 10:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/39\">",
"      LeLeiko RM, Vaccari CS, Sola S, et al. Usefulness of elevations in serum choline and free F2)-isoprostane to predict 30-day cardiovascular outcomes in patients with acute coronary syndrome. Am J Cardiol 2009; 104:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/40\">",
"      Hokamaki J, Kawano H, Yoshimura M, et al. Urinary biopyrrins levels are elevated in relation to severity of heart failure. J Am Coll Cardiol 2004; 43:1880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/41\">",
"      Landmesser U, Spiekermann S, Dikalov S, et al. Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: role of xanthine-oxidase and extracellular superoxide dismutase. Circulation 2002; 106:3073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/42\">",
"      Colombo PC, Banchs JE, Celaj S, et al. Endothelial cell activation in patients with decompensated heart failure. Circulation 2005; 111:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/43\">",
"      Valgimigli M, Merli E, Malagutti P, et al. Hydroxyl radical generation, levels of tumor necrosis factor-alpha, and progression to heart failure after acute myocardial infarction. J Am Coll Cardiol 2004; 43:2000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/44\">",
"      Anker SD, Doehner W, Rauchhaus M, et al. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation 2003; 107:1991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/45\">",
"      Krishnan E. Hyperuricemia and incident heart failure. Circ Heart Fail 2009; 2:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/46\">",
"      Doehner W, Schoene N, Rauchhaus M, et al. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation 2002; 105:2619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/47\">",
"      Ahmed MI, Gladden JD, Litovsky SH, et al. Increased oxidative stress and cardiomyocyte myofibrillar degeneration in patients with chronic isolated mitral regurgitation and ejection fraction &gt;60%. J Am Coll Cardiol 2010; 55:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/48\">",
"      Heymes C, Bendall JK, Ratajczak P, et al. Increased myocardial NADPH oxidase activity in human heart failure. J Am Coll Cardiol 2003; 41:2164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/49\">",
"      Sam F, Kerstetter DL, Pimental DR, et al. Increased reactive oxygen species production and functional alterations in antioxidant enzymes in human failing myocardium. J Card Fail 2005; 11:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/50\">",
"      Nakamura K, Kusano KF, Matsubara H, et al. Relationship between oxidative stress and systolic dysfunction in patients with hypertrophic cardiomyopathy. J Card Fail 2005; 11:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/51\">",
"      Lu Z, Xu X, Hu X, et al. Oxidative stress regulates left ventricular PDE5 expression in the failing heart. Circulation 2010; 121:1474.",
"     </a>",
"    </li>",
"    <li>",
"     Halliwell B, Gatteridge JM. Free Radicals in Biology and Medicine, Oxford University Press, Oxford 1989.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/53\">",
"      McCord JM. Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med 1985; 312:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/54\">",
"      Hare JM, Johnson RJ. Uric acid predicts clinical outcomes in heart failure: insights regarding the role of xanthine oxidase and uric acid in disease pathophysiology. Circulation 2003; 107:1951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/55\">",
"      Gioda CR, de Oliveira Barreto T, Pr&iacute;mola-Gomes TN, et al. Cardiac oxidative stress is involved in heart failure induced by thiamine deprivation in rats. Am J Physiol Heart Circ Physiol 2010; 298:H2039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/56\">",
"      Predmore JM, Wang P, Davis F, et al. Ubiquitin proteasome dysfunction in human hypertrophic and dilated cardiomyopathies. Circulation 2010; 121:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/57\">",
"      Venardos KM, Zatta AJ, Marshall T, et al. Reduced L-arginine transport contributes to the pathogenesis of myocardial ischemia-reperfusion injury. J Cell Biochem 2009; 108:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/58\">",
"      Griendling KK, Alexander RW. Oxidative stress and cardiovascular disease. Circulation 1997; 96:3264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/59\">",
"      Taniyama Y, Griendling KK. Reactive oxygen species in the vasculature: molecular and cellular mechanisms. Hypertension 2003; 42:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/60\">",
"      Keaney JF Jr, Larson MG, Vasan RS, et al. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol 2003; 23:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/61\">",
"      Frei B, England L, Ames BN. Ascorbate is an outstanding antioxidant in human blood plasma. Proc Natl Acad Sci U S A 1989; 86:6377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/62\">",
"      Blanchard J, Tozer TN, Rowland M. Pharmacokinetic perspectives on megadoses of ascorbic acid. Am J Clin Nutr 1997; 66:1165.",
"     </a>",
"    </li>",
"    <li>",
"     Keaney JF JR, Frei B. Antioxidant protection of low-density lipoprotein and its role in the prevention of atherosclerotic vascular disease. In: Natural antioxidants in human health and disease, Frei B (Ed), Academic Press, San Diego 1994. p.303.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/64\">",
"      Erbs S, Gielen S, Linke A, et al. Improvement of peripheral endothelial dysfunction by acute vitamin C application: different effects in patients with coronary artery disease, ischemic, and dilated cardiomyopathy. Am Heart J 2003; 146:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/65\">",
"      Tomiyama H, Watanabe G, Yoshida H, et al. Reduction of oxidative stress augments natriuretic effect of furosemide in moderate heart failure. Am Heart J 2003; 145:E2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/66\">",
"      Shinke T, Shite J, Takaoka H, et al. Vitamin C restores the contractile response to dobutamine and improves myocardial efficiency in patients with heart failure after anterior myocardial infarction. Am Heart J 2007; 154:645.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/67\">",
"      Mak S, Newton GE. Redox modulation of the inotropic response to dobutamine is impaired in patients with heart failure. Am J Physiol Heart Circ Physiol 2004; 286:H789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/68\">",
"      Hornig B, Arakawa N, Kohler C, Drexler H. Vitamin C improves endothelial function of conduit arteries in patients with chronic heart failure. Circulation 1998; 97:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/69\">",
"      Ellis GR, Anderson RA, Lang D, et al. Neutrophil superoxide anion--generating capacity, endothelial function and oxidative stress in chronic heart failure: effects of short- and long-term vitamin C therapy. J Am Coll Cardiol 2000; 36:1474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/70\">",
"      Steiner M. Influence of vitamin E on platelet function in humans. J Am Coll Nutr 1991; 10:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/71\">",
"      Rifici VA, Khachadurian AK. Dietary supplementation with vitamins C and E inhibits in vitro oxidation of lipoproteins. J Am Coll Nutr 1993; 12:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/72\">",
"      Keaney JF Jr, Xu A, Cunningham D, et al. Dietary probucol preserves endothelial function in cholesterol-fed rabbits by limiting vascular oxidative stress and superoxide generation. J Clin Invest 1995; 95:2520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/73\">",
"      Tardif JC, Gr&eacute;goire J, Schwartz L, et al. Effects of AGI-1067 and probucol after percutaneous coronary interventions. Circulation 2003; 107:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/74\">",
"      Li T, Singal PK. Adriamycin-induced early changes in myocardial antioxidant enzymes and their modulation by probucol. Circulation 2000; 102:2105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/75\">",
"      Nakamura R, Egashira K, Machida Y, et al. Probucol attenuates left ventricular dysfunction and remodeling in tachycardia-induced heart failure: roles of oxidative stress and inflammation. Circulation 2002; 106:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/76\">",
"      Watson PS, Scalia GM, Galbraith A, et al. Lack of effect of coenzyme Q on left ventricular function in patients with congestive heart failure. J Am Coll Cardiol 1999; 33:1549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/77\">",
"      Khatta M, Alexander BS, Krichten CM, et al. The effect of coenzyme Q10 in patients with congestive heart failure. Ann Intern Med 2000; 132:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/78\">",
"      Farquharson CA, Butler R, Hill A, et al. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation 2002; 106:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/79\">",
"      George J, Carr E, Davies J, et al. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation 2006; 114:2508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/80\">",
"      Cappola TP, Kass DA, Nelson GS, et al. Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation 2001; 104:2407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/81\">",
"      Minhas KM, Saraiva RM, Schuleri KH, et al. Xanthine oxidoreductase inhibition causes reverse remodeling in rats with dilated cardiomyopathy. Circ Res 2006; 98:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/82\">",
"      Hirsch GA, Bottomley PA, Gerstenblith G, Weiss RG. Allopurinol acutely increases adenosine triphospate energy delivery in failing human hearts. J Am Coll Cardiol 2012; 59:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/83\">",
"      Liu C, Cao F, Tang QZ, et al. Allicin protects against cardiac hypertrophy and fibrosis via attenuating reactive oxygen species-dependent signaling pathways. J Nutr Biochem 2010; 21:1238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/84\">",
"      Yue TL, Cheng HY, Lysko PG, et al. Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther 1992; 263:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/85\">",
"      Kukin ML, Kalman J, Charney RH, et al. Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation 1999; 99:2645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/86\">",
"      Nakamura K, Kusano K, Nakamura Y, et al. Carvedilol decreases elevated oxidative stress in human failing myocardium. Circulation 2002; 105:2867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/87\">",
"      Cohen-Solal A, Rouzet F, Berdeaux A, et al. Effects of carvedilol on myocardial sympathetic innervation in patients with chronic heart failure. J Nucl Med 2005; 46:1796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/88\">",
"      Sun Y, Zhang J, Lu L, et al. Aldosterone-induced inflammation in the rat heart : role of oxidative stress. Am J Pathol 2002; 161:1773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/89\">",
"      Keidar S, Hayek T, Kaplan M, et al. Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and atherosclerosis in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 2003; 41:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/90\">",
"      Yamanaka S, Tatsumi T, Shiraishi J, et al. Amlodipine inhibits doxorubicin-induced apoptosis in neonatal rat cardiac myocytes. J Am Coll Cardiol 2003; 41:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/91\">",
"      Daiber A, Oelze M, Coldewey M, et al. Hydralazine is a powerful inhibitor of peroxynitrite formation as a possible explanation for its beneficial effects on prognosis in patients with congestive heart failure. Biochem Biophys Res Commun 2005; 338:1865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/92\">",
"      M&uuml;nzel T, Kurz S, Rajagopalan S, et al. Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug. J Clin Invest 1996; 98:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/93\">",
"      Sasaki H, Asanuma H, Fujita M, et al. Metformin prevents progression of heart failure in dogs: role of AMP-activated protein kinase. Circulation 2009; 119:2568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/94\">",
"      Linke A, Adams V, Schulze PC, et al. Antioxidative effects of exercise training in patients with chronic heart failure: increase in radical scavenger enzyme activity in skeletal muscle. Circulation 2005; 111:1763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/95\">",
"      Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119:e391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/96\">",
"      Bolli R, Jeroudi MO, Patel BS, et al. Marked reduction of free radical generation and contractile dysfunction by antioxidant therapy begun at the time of reperfusion. Evidence that myocardial \"stunning\" is a manifestation of reperfusion injury. Circ Res 1989; 65:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/97\">",
"      Gross GJ, O'Rourke ST, Pelc LR, Warltier DC. Myocardial and endothelial dysfunction after multiple, brief coronary occlusions: role of oxygen radicals. Am J Physiol 1992; 263:H1703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/98\">",
"      Sia YT, Parker TG, Liu P, et al. Improved post-myocardial infarction survival with probucol in rats: effects on left ventricular function, morphology, cardiac oxidative stress and cytokine expression. J Am Coll Cardiol 2002; 39:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/99\">",
"      Redout EM, van der Toorn A, Zuidwijk MJ, et al. Antioxidant treatment attenuates pulmonary arterial hypertension-induced heart failure. Am J Physiol Heart Circ Physiol 2010; 298:H1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/100\">",
"      Hamblin M, Smith HM, Hill MF. Dietary supplementation with vitamin E ameliorates cardiac failure in type I diabetic cardiomyopathy by suppressing myocardial generation of 8-iso-prostaglandin F2alpha and oxidized glutathione. J Card Fail 2007; 13:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/101\">",
"      Nightingale AK, Crilley JG, Pegge NC, et al. Chronic oral ascorbic acid therapy worsens skeletal muscle metabolism in patients with chronic heart failure. Eur J Heart Fail 2007; 9:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/102\">",
"      Keith ME, Jeejeebhoy KN, Langer A, et al. A controlled clinical trial of vitamin E supplementation in patients with congestive heart failure. Am J Clin Nutr 2001; 73:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/103\">",
"      Lonn E, Bosch J, Yusuf S, et al. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA 2005; 293:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/104\">",
"      Tousoulis D, Antoniades C, Vassiliadou C, et al. Effects of combined administration of low dose atorvastatin and vitamin E on inflammatory markers and endothelial function in patients with heart failure. Eur J Heart Fail 2005; 7:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/105\">",
"      Hare JM, Mangal B, Brown J, et al. Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study. J Am Coll Cardiol 2008; 51:2301.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.clinicaltrials.gov/ct2/show/NCT00987415.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/107\">",
"      Parissis JT, Kourea K, Andreadou I, et al. Effects of Darbepoetin Alfa on plasma mediators of oxidative and nitrosative stress in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 2009; 103:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/108\">",
"      Alameddine FM, Zafari AM. Genetic polymorphisms and oxidative stress in heart failure. Congest Heart Fail 2002; 8:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/44/27337/abstract/109\">",
"      Iida S, Chu Y, Francis J, et al. Gene transfer of extracellular superoxide dismutase improves endothelial function in rats with heart failure. Am J Physiol Heart Circ Physiol 2005; 289:H525.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3471 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.25.216.6-05F6B74FED-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_44_27337=[""].join("\n");
var outline_f26_44_27337=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ROLE OF OXIDATIVE STRESS IN MYOCARDIAL FAILURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Animal studies of oxidative stress and heart failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Oxidative stress in human heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ROLE OF ANTIOXIDANTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Specific agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Vitamin C",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Vitamin E",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Probucol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Coenzyme Q10",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Allopurinol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Allicin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Heart failure medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Potential therapy for heart failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Animal studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Human trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/3471\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3471|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/1/40989\" title=\"table 1\">",
"      ACC AHA Rx systolic HF",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=related_link\">",
"      Cardiotoxicity of anthracycline-like chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18138?source=related_link\">",
"      Lipoprotein classification; metabolism; and role in atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26456?source=related_link\">",
"      Nutritional antioxidants in coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/12/28871?source=related_link\">",
"      Overview of vitamin E",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/62/28650?source=related_link\">",
"      Overview of water-soluble vitamins",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_44_27338="Bullous pemphigoid pathology";
var content_f26_44_27338=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F66267%7EDERM%2F86373&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F66267%7EDERM%2F86373&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bullous pemphigoid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 312px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This hematoxylin and eosin stain of a skin&nbsp;tissue biopsy specimen from the edge of an established lesion of bullous pemphigoid demonstrates a subepidermal blister with an edematous papillary dermis as its base. The roof of the blister consists of the intact epidermis, including the stratum basalis. Eosinophil-rich inflammatory cells, fibrin, and tissue fluid fill the blister.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Rubin, E, Farber, JL. Pathology, 3rd ed, Lippincott Williams &amp; Wilkins, Philadelphia 1999. Copyright &copy;1999 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Direct immunofluorescence microscopy of bullous pemphigoid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Direct immunofluorescence microscopy reveals linear IgG and C3 basement membrane zone staining (IgG shown here). 200 X.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kristin M Leiferman, MD, Immunodermatology Laboratory, Department of Dermatology, University of Utah, Salt Lake City, Utah.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_44_27338=[""].join("\n");
var outline_f26_44_27338=null;
var title_f26_44_27339="Stage distribution for gallbladder cancer";
var content_f26_44_27339=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F71493&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F71493&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Stage distribution for 439 incidentally found gallbladder cancers in a German registry, according to type of surgery performed",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Pathologic T (tumor) stage",
"       </td>",
"       <td class=\"subtitle1\">",
"        Laparoscopic, percent",
"        <br/>",
"        (n = 239)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Open resection, percent",
"        <br/>",
"        (n = 131)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Conversion from laparoscopic to open resection*",
"        <br/>",
"        (n = 69)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        pTis",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        pT1",
"       </td>",
"       <td>",
"        21",
"       </td>",
"       <td>",
"        21",
"       </td>",
"       <td>",
"        19",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        pT2",
"       </td>",
"       <td>",
"        56",
"       </td>",
"       <td>",
"        38",
"       </td>",
"       <td>",
"        24",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        pT3",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        19",
"       </td>",
"       <td>",
"        46",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        pT4",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        pTx",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Conversion to an open procedure for non-oncologic reasons.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Ann Surg 2008; 247:104.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_44_27339=[""].join("\n");
var outline_f26_44_27339=null;
var title_f26_44_27340="Specimen collection methods II";
var content_f26_44_27340=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F54592&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F54592&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Microbiology specimen handling and collection - II",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Specimen",
"       </td>",
"       <td class=\"subtitle1\">",
"        Method",
"       </td>",
"       <td class=\"subtitle1\">",
"        Volume",
"       </td>",
"       <td class=\"subtitle1\">",
"        Storage temperature*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Genital",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fluids -&nbsp;endometrial, amniotic, pelvic (culdocentesis)",
"       </td>",
"       <td>",
"        Sterile anaerobic container",
"       </td>",
"       <td>",
"        1-10 mL",
"       </td>",
"       <td>",
"        4&ordm;C",
"       </td>",
"       <td>",
"        Anaerobic culture is appropriate only for specimens obtained without traversing colonized areas (eg, vagina).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chlamydia trachomatis",
"       </td>",
"       <td>",
"        Swab or chlamydia transport medium",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        4&ordm;C",
"       </td>",
"       <td>",
"        Choice of swab depends upon test method (culture, EIA, DFA, molecular amplification). For culture specimens, avoid cotton swab on wooden stick.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Herpes simplex virus",
"       </td>",
"       <td>",
"        Swab in viral transport media",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        4&ordm;C",
"       </td>",
"       <td>",
"        <span style=\"line-height: 115%; font-family: calibri,sans-serif; font-size: 11pt;\">",
"         Choice of swab depends upon test method (culture, DFA, molecular amplification).",
"        </span>",
"        For culture specimens, avoid cotton swab on wooden stick and calcium alginate swab.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Neisseria gonorrheae",
"       </td>",
"       <td>",
"        Inoculate selective medium or transport kit immediately",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        25&ordm;C",
"       </td>",
"       <td>",
"        For culture specimens, use CO2 transport kits or devices and do not refrigerate.",
"        <span style=\"line-height: 115%; font-family: calibri,sans-serif; font-size: 11pt;\">",
"         For molecular detection, use rayon or Dacron-tipped swab.",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vaginal",
"       </td>",
"       <td>",
"        Swab",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        4&ordm;C",
"       </td>",
"       <td>",
"        For Trichomonas, Candida, etc.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Genitourinary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Prostate",
"       </td>",
"       <td>",
"        Prostatic massage specimens in sterile container",
"       </td>",
"       <td>",
"        1-5 mL",
"       </td>",
"       <td>",
"        4&ordm;C",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * If immediate processing is not possible.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_44_27340=[""].join("\n");
var outline_f26_44_27340=null;
var title_f26_44_27341="Contents: Obstetrics calculators";
var content_f26_44_27341=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?0/37/606\">",
"       Calculators",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Obstetrics calculators",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Obstetrics calculators",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Medical Equations",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/5/42067\">",
"           Calculator: Estimated Date of Delivery (EDD)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/15/21759\">",
"           Calculator: Estimated Date of Delivery (EDD) (Patient information)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/55/9074\">",
"           Calculator: Gestational age from Estimated Date of Delivery (EDD)",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-C480B6046D-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f26_44_27341=[""].join("\n");
var outline_f26_44_27341=null;
var title_f26_44_27342="Metacarpal neck fx lateral";
var content_f26_44_27342=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F53210&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F53210&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    5th metacarpal neck fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 384px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This lateral radiograph of the hand shows a comminuted fracture of the 5th metacarpal (MC) neck with apex dorsal angulation. In addition to the abnormal volar location of the MC head (black arrow) there is a fragment of the shaft seen as well (white arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kevin Burroughs, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_44_27342=[""].join("\n");
var outline_f26_44_27342=null;
var title_f26_44_27343="Color Doppler HCM with MR and LVOT obstruction";
var content_f26_44_27343=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F78478&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F78478&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Color Doppler echocardiography showing left ventricular outflow tract (LVOT) obstruction and mitral regurgitation (MR) in a patient with hypertrophic cardiomyopathy (HCM)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 299px; height: 266px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The apical view from a two dimensional echocardiogram with color flow Doppler in a patient with hypertrophic cardiomyopathy and left ventricular outflow tract obstruction shows turbulence in the outflow tract caused by contact between the anterior mitral valve leaflet and the interventricular septum. As a consenquence of the systolic anterior motion of the mitral valve, there is abnormal coaptation of the mitral leaflets, resulting in a posteriory directed jet of mitral regurgitation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Perry Elliot, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_44_27343=[""].join("\n");
var outline_f26_44_27343=null;
